Published in final edited form as:

J Med Chem. 2017 February 09; 60(3): 1089–1104. doi:10.1021/acs.jmedchem.6b01448.

Pyrimidinyl Biphenylureas: Identification of New Lead Compounds as Allosteric Modulators of the Cannabinoid Receptor CB₁

Leepakshi Khurana[†], Bo-Qiao Fu[‡], Anantha L. Duddupudi[‡], Yu-Hsien Liao[†], Sri Sujana Immadi[‡], Debra A. Kendall^{*,†}, and Dai Lu^{*,‡}

[†]Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut 06269, United States

[‡]Rangel College of Pharmacy, Health Science Center, Texas A&M University, 1010 West Avenue B, Kingsville, Texas 78363, United States

Abstract

The allosteric modulator 1-(4-chlorophenyl)-3-(3-(6-(pyrrolidin-1-yl)pyridin-2-yl)phenyl)urea (PSNCBAM-1, **2**) bound the cannabinoid receptor 1 (CB₁) and antagonized G protein coupling. This compound demonstrated potent anorectic effects similar to the CB₁ antagonist rimonabant that once was marketed for the treatment of obesity, suggesting a new chemical entity for the discovery of antiobesity drugs. To increase structural diversity of this class of CB₁ ligands, we designed and synthesized two classes of novel analogues, in which the pyridine ring of **2** was replaced by a pyrimidine ring. These positively modulate the binding of the CB₁ orthosteric agonist CP55,940 while exhibiting an antagonism of G-protein coupling activity. Interestingly, compounds **7d** and **8d** demonstrated ERK1/2 phosphorylation mediated via β -arrestin unlike the orthosteric CP55,940 that does so in a G protein-dependent manner. These can serve as new lead compounds for the future development of CB₁ allosteric modulators that show biased agonism and potentially antiobesity behavior via a new mechanism.

Graphical Abstract

*Corresponding Authors: For D.L.: phone, (361) 221-0745; fax, (361) 221-0793; dlu@tamhsc.edu. For D.A.K.: phone, (860) 486-1891; fax, (860) 486-5792; debra.kendall@uconn.edu.

ORCID

Dai Lu: 0000-0003-2630-3184

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. Experiments were carried out by L.K., A-L. D., B-Q. F., Y-H. L., and S.S.I.

Notes

The authors declare no competing financial interest.

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmed-chem.6b01448.

The spectra of 1D and 2D ¹H NMR of compounds **11**, **16f**, **17f**, **16g**, and **17g** and the methods and results of HPLC analysis of compounds **8c**, **8h**, **8j**, **8l**, **8n**, **8o**, and **8p** (PDF)

Molecular formula strings (CSV)

INTRODUCTION

The endocannabinoid system (ECS) consists of two well-characterized receptor subtypes, the cannabinoid receptor 1 (CB₁) and the cannabinoid receptor 2 (CB₂), the eicosanoid ligands synthesized in the body called endocannabinoids, and several metabolic proteins (e.g., fatty acid amide hydrolase, monoacylglycerol lipase).¹ Both the receptors are activated by ⁹-tetrahydrocannabinol (THC), the psychoactive component of marijuana (*Cannabis sativa*) and belong to class 1A rhodopsin-like G-protein coupled receptors (GPCRs). Moreover, CB₁ is one of the most abundant GPCRs expressed in the central nervous system (CNS).^{2,3} Upon activation, the CB₁ receptor primarily couples to G_{i/o} protein, which causes downstream inhibition of adenylyl cyclase. The CB₁ receptor can also activate inwardly rectifying and A-type outward potassium channels^{4,5} and inhibit N-type and P/Q type of calcium channels.^{6,7} The CB₁ receptor can also activate different members of mitogen-activated protein kinases including p44/42 MAP kinase, p38 kinase, and JUN-terminal kinase through G-protein mediated pathways or pathways independent of G-proteins via β -arrestins.^{8,9} Because of its complex signaling network, CB₁ has been implicated in the pathology of many disorders and thus is a promising therapeutic target for ameliorating diseases including nausea, obesity, neurodegenerative disorders, pain, and substance abuse disorders.^{8,10} However, despite extensive efforts to generate cannabinoid-based therapeutics, only a few medications from cannabinergic compounds are commercially available due to the extensive side effects associated with CB₁ orthosteric ligands.¹¹ Another CB₁ ligand, SR141716A (rimonabant), which was initially developed as an antiobesity drug, was withdrawn from the market due to its psychiatric side effects.¹²

To overcome challenges posed by orthosteric ligands (ligands which compete with the endogenous ligands for the same site), recent research in GPCRs including CB₁ has shifted focus to allosteric modulators that bind to a topographically distinct site called the allosteric site. Allosteric modulators offer many therapeutic advantages over their orthosteric counterparts. First, because of less evolutionary pressure, allosteric binding pockets have amino acid sequences which are not highly conserved like the orthosteric sites and thus are more specific for each receptor subtype. Second, allosteric modulators have a ceiling effect due to their limited allosteric cooperativity and thus can be used to generate titrated pharmacological responses.^{13,14} Third, allosteric modulators can be used to fine-tune endogenous signaling without affecting the spatial and temporal aspects of endogenous ligand–receptor signaling.¹⁵

Allosteric modulators, upon binding to a receptor, can induce an array of distinct conformations that can be very different from those stabilized by orthosteric ligands and thus have expanded the spectrum of biological conformations among the inactive and active states. Several classes of allosteric modulators of CB₁ have been identified (Figure 1), which include 5-chloro-3-ethyl-*N*-(4-(piperidin-1-yl)phenethyl)-1*H*-indole-2-carboxamide (**1**, ORG27569),¹⁶ 1-(4-chlorophenyl)-3-(3-(6-(pyrrolidin-1-yl)pyridin-2-yl)phenyl)urea (**2**, PSNCBAM-1),¹⁷ 3-(4-chlorophenyl)-5-(8-methyl-3-*p*-tolyl-8-azabicyclo[3.2.1]octan-2-yl)isoxazole (**3**, RTI-371),¹⁸ the endogenous ligand (5*S*,6*R*,9*E*,11*Z*,13*E*,15*S*)-5,6,15-trihydroxyico-sa-9,11,13-trienoic acid (**4**, lipoxin A4),¹⁹ and 6-methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1*H*-indole (**5**, ZCZ011).²⁰ These ligands are positive allosteric modulators (PAMs) of orthosteric agonist binding at the CB₁ receptor. A family of peptide endocannabinoids (Pepcans) represented by pepcan-12 (**6**) has recently been reported to exhibit negative allosteric modulation (NAM) of the CB₁ receptor at the level of regulating orthosteric agonist binding as well as the signaling functions of CB₁ receptor.²¹ Because allosteric modulators can induce distinct conformations than those induced by orthosteric ligands, they offer potential to generate pharmacological responses that may be difficult to achieve with orthosteric ligands alone. Furthermore, the different receptor states induced by allosteric modulators can be biased for coupling to different G proteins or β -arrestin, likely due to the different conformations they induce. This can impact some intracellular signaling pathways as is seen with some allosteric modulators including **1** for the CB₁ receptor and consequently offer promising avenues to develop subtype-specific and pathway-specific therapeutics.^{22,23}

Some in vivo pharmacological assessments have indicated that these allosteric modulators can generate therapeutic effects relevant to various clinical therapies. For instance, **1** was demonstrated to be effective in inhibiting reinstatement of drug-seeking behavior²⁴ and **4** was found to reduce β -amyloid-provoked neurotoxicity.¹⁹ The positive CB₁ allosteric modulator **5** was shown to generate antinociceptive effects without psychoactive effects typically found with orthosteric ligands of the CB₁ receptor.²⁰ Interestingly, **2** was found capable of reducing food intake and body weight in an acute feeding study.¹⁷ Thus, this scaffold holds promise for the development of antiobesity drugs by targeting CB₁ allosteric sites. A recent SAR study of **2** has revealed that two structural variations can preserve its activity. These include the replacement of the chloro group on the ring A with either a fluoro (F) or a cyano (CN) group and the replacement of the pyrrolidine ring with a *N,N*-dimethyl amino group. These analogues exhibited a dose- dependent reduction of E_{max} values with the agonist CP55,940 in a calcium mobilization assay, as expected for CB₁ G protein NAMs.²⁵ To increase the structural diversity from this scaffold, we designed novel analogues with the hypothesis that a pyrimidinyl ring can be employed to replace the pyridine ring of **2**. This hypothesis was supported by two considerations. First, many allosteric modulators of various GPCRs possess cyclic moieties that contain multiple nitrogen atoms.²⁶ The pyrimidine moiety has been found in a number of allosteric modulators of different GPCRs such as for the glucagon-like peptide 1 (GLP-1) receptor,²⁷ the metabotropic glutamate receptor 5 (mGluR₅),²⁸ and the γ -aminobutyric acid_B (GABA_B) receptor²⁹ among others.³⁰ Second, in comparison with pyridine, the pyrimidine structure offers more synthetic versatility. The π -electron density is decreased to an even greater

extent than in pyridine.³¹ Therefore, nucleophilic aromatic substitution is facilitated. Synthetically, the electron-deficient nature of pyrimidine accounts for better opportunities when nucleophilic aromatic substitution chemistry is employed in functionalization of the electron-deficient heteroaromatic ring.³¹ On the basis of the above features, we synthesized and assessed novel analogues **7a–7h** and **8a–8t** whose structures are shown in Figure 2.

CHEMISTRY

The syntheses of the target compounds **7** and **8** were achieved through the routes illustrated by Schemes 1 and 2, respectively. To obtain compounds **7a–7h**, the synthesis of intermediate 3-(2-chloropyrimidin-4-yl)aniline **12** was critical. Coupling of the commercially available 2,4-dichloropyrimidine **9** with (3-nitrophenyl)boronic acid **10** under typical Suzuki reaction conditions exclusively gave the 2-chloro-4-(3-nitrophenyl)-pyrimidine **11**. We found that this Suzuki coupling reaction only took place at the 4-chloro position of the starting material **9** while its 2-chloro group was spared. The structure of the Suzuki coupling product **11** was confirmed by NOESY signals between the protons H-8 and H-12 with proton H-5 of **11** (see Supporting Information, Figure S3, for 2D ¹H NMR of **11**). Upon reduction of **11** catalyzed with stannous chloride dihydrate, the desired intermediate 3-(2-chloropyrimidin-4-yl)aniline **12** was obtained in an acceptable yield (40%). Reaction of the pyrimidinyl aniline **12** with properly substituted isocyanate (**13a–13f**) yielded the key intermediates **14a–14f**. Thereafter, amination of the pyrimidinyl ring of individual **14** with either pyrrolidine or dimethyl amine in THF generated the final compounds **7a–7h**.

Because the Suzuki coupling reaction between **9** and **10** could not lead to the intermediate that can provide the desired amine **19**, we took the route illustrated in Scheme 2 and aminated the 2,4-dichloropyrimidine **9** first. This yielded two regioisomers **16** and **17**. The 4-amino pyrimidine **16** was obtained as the major product, while the 2-amino pyrimidine **17** was the minor product. The structures of individual isomers (i.e., **16a–16g** and **17a–17g**) were either verified by comparison with the NMR data reported in the literature or determined by 2D ¹H NMR (see Supporting Information). Coupling the 4-amino pyrimidine **16a–16g**, respectively, with (3-nitrophenyl)boronic acid **10** under Suzuki reaction conditions yielded the desired 2-(3-nitrophenyl)pyrimidin-4-amines **18a–18g** in acceptable yields (46%–75%). Hydrogenation of **18a–18g** produced the 2-(3-aminophenyl)-pyrimidin-4-amines **19a–19g** in good yield (87–97%). Coupling the selected isocyanates **13g–13k** with amines **19a–19g** yielded the final compounds **8a–8k**, **8m**, and **8o–t**. The carboxylic acid **8l** was further derived from **8k** through hydrolysis, and **8n** was obtained from demethylation of **8m**.

RESULTS AND DISCUSSION

The synthesized analogues were evaluated for allosteric modulation of CB₁, using the orthosteric agonist CP55,940, and two key parameters were determined: *K_B*, the equilibrium dissociation constant of the allosteric modulator which reflects the affinity of the allosteric modulator for the receptor, and *α*, the binding cooperativity factor which defines the magnitude and direction of the allosteric effect on the binding of the orthosteric ligand when both occupy the receptor. Modulators with an *α* > 1 promote orthosteric ligand binding and

are classified as positive allosteric modulators (PAMs), whereas modulators with $\alpha < 1$ inhibit orthosteric ligand binding and are classified as negative allosteric modulators (NAMs). Compounds with no allosteric activity on orthosteric ligand binding have an $\alpha = 1$.

To evaluate the scaffolds **7** and **8**, we first compared **7a** and **8a** with the lead compound **2**. The results, shown in Tables 1 and 2 (entries 2 and 10), suggested that replacing the pyridine ring of **2** with a pyrimidine ring reduced the binding affinity relative to the parent compound while the modulation on orthosteric ligand binding was enhanced (i.e., the α values are increased). This promoted our further investigation of the two new scaffolds by optimizing the substituents. We synthesized and assessed compounds **7b–7h** and their counterpart compounds **8b–8h**. The results shown in Table 1 (entries 3–9) and Table 2 (entries 11–17) revealed that the scaffolds **7** and **8** do not show significant difference in binding affinity (K_B) and binding cooperativity factor (α) when compounds with the same substitutions on the two different scaffolds are compared. However, the binding affinity is significantly influenced by the substitution on the phenyl ring A and the amino substituent on the pyrimidine ring C. We found that a *para*-cyano group on the phenyl ring A and a pyrrolidinyl group on the pyrimidine ring C provided a compound (i.e., **8d**) that showed activity comparable to the lead compound **2**. It also appears that a dimethyl amino substituent on the pyrimidinyl ring C is more suboptimal than a pyrrolidinyl group within each series of compounds from scaffolds **7** and **8**.

A cyano group is a strong electron-withdrawing group (EWG). To investigate if other substituents on the phenyl ring A can increase the binding affinity and cooperativity, we synthesized and assessed the compounds **8i–8n** (Table 2, entry 18–23), which bear either an EWG such as CF_3 (**8i**), acetyl (**8j**), ethoxyacetyl (**8k**), and COOH (**8l**) or an electron-donating group (EDG) such as OMe (**8m**) and OH (**8n**). However, none of them surpassed the cyano-substituted compound **8d**. Introducing EDGs on the phenyl ring A (i.e., compound **8m** and **8n**) significantly reduced the binding affinity to the allosteric site. Some of the EWGs are able to retain some binding affinity to the allosteric site (i.e., **8i** and **8k**). These suggested that variation of the electron density of the phenyl ring A alone is unable to enhance the binding affinity. It seems that the electron-withdrawing cyano group is not only to polarize the adjacent electron density on the ring A but is also likely involved in the molecular recognition process. The multiple biological functions of a cyano group have been well recognized.³² Its functions include serving as carbonyl and halogen bioisosteres, a hydroxyl and carboxyl surrogate, an inducer of nonspecific dipole interactions with amino acids and metal ions, and a functionality able to replace a conserved water molecule from the binding domain.³² Expulsion of a conserved water molecule from the binding domain by a cyano group has been indicated to provide additional entropic improvement of binding affinity.^{33,34} Additionally, we found that the position of the cyano substitution impacts the allosteric activity drastically. When the cyano group on the ring A of **8** was shifted from the *para*-position to the *meta*-position, the binding affinity to the allosteric site and the allosteric modulation of orthosteric ligand binding were nearly abolished (i.e., **8d** vs **8o**, Table 2).

Following the identification of **8d**, we investigated if other amino substituents on the pyrimidine ring can enhance activity (Table 3). We reduced the ring size to a four-membered azetidiny ring (**8p**). This led to a decline in K_B . When the ring size was increased to a six-

membered piperidinyl ring (**8q**), it showed a K_B comparable to **8d** with slightly reduced binding cooperativity factor (α). This promoted our synthesis of analogues with acyclic amino substituents of the pyrimidinyl ring (i.e., **8r–8t**). The results (entries 27–29, Table 3) indicated that only the *N,N*-diethyl amino group (**8r**) preserve the activity of **8d**. The results from **8r** to **8t** suggested that a dialkyl amino group is preferred as the substituent on the pyrimidinyl ring C and each of the alkyl substitutions should be greater than methyl.

The allosteric binding parameters of the compounds suggest using pyrimidine in lieu of the pyridine ring led to two compounds (i.e., **8d** and **8r**) showing similar binding affinity (K_B) to an allosteric site as the lead compound **2**. Their allosteric effects on orthosteric agonist binding (i.e., the α values) are comparable to **2**. To further investigate the value of these novel allosteric modulators, compounds **7a** and **8a**, **7d** and **8d** and **8r** were compared with **2** via [³⁵S]GTP γ S binding activity indicative of G protein coupling. The results are shown in Figure 3. All of these tested compounds showed a concentration-dependent inhibition of CP55,940-induced GTP γ S binding. In this functional assay, compounds **7a** and **8a** are weaker than **2** in reducing the G-protein coupling to the CB1 receptor. In contrast, compounds **7d** (Figure 3D) and **8d** (Figure 3E) showed a potency comparable to **2** in reducing the G-protein coupling. Notably, although **7d** has a weaker binding affinity for the allosteric site than **8d** and **8r**, it displayed a reduction in G protein coupling comparable to **8d** and **2** in the functional assay. This was indicated by their relative reduction in G protein coupling at the 0.3 μ M testing concentration in the [³⁵S]GTP γ S binding assay. In each assay in Figure 3, cells not transfected and transfected with the CB1 receptor treated with the inverse agonist SR141716A are also given. As expected, the latter reduces the [³⁵S]GTP γ S activity below the basal (constitutive activity in the absence of ligand) level of coupling activity. In combination with the allosteric binding parameters, we conclude that compounds **7d** and **8d** are viable CB₁ allosteric modulators, showing a binding profile and functional activity similar to **2**.

Because the compounds tested antagonize the CP55,940-induced G protein coupling, we determined if signaling via β -arrestin, instead of G protein, was utilized. For this purpose, we used ERK1/2 phosphorylation as a good earmark of cellular signaling that can exhibit both G-protein dependent and G-protein independent phosphorylation.^{35,36} Consistent with previous observations, ERK1/2 phosphorylation induced by treatment with the orthosteric agonist CP55,940 alone for 5 min was substantially reduced by G protein-sensitive pertussis toxin (PTX). However, knockdown of β -arrestin 1 or 2 did not impact ERK1/2 phosphorylation by CP55940, collectively indicating phosphorylation by this compound alone is G_i-mediated (Figure 4).⁹ However, treatment with the allosteric modulators **7d** and **8d** alone demonstrated ERK1/2 phosphorylation was insensitive to treatment by PTX, indicating that phosphorylation of ERK1/2 induced by these allosteric modulators is not G_i-mediated. This is consistent with the results showing inhibition of G-protein coupling shown for these allosteric modulators (Figure 3 above). Interestingly, knockdown of β -arrestin-1 with siRNA attenuated ERK1/2 phosphorylation by the modulators **7d** and **8d**. Compound **2** exhibited a similar response shown for comparison.^{37,38} These results, and the enhancement in binding of the orthosteric agonist CP55,940, suggest that these compounds are PAMs and

promote an active state of the receptor that may be biased to signal via β -arrestin-1 (at least for ERK1/2 phosphorylation) and not G protein.

CONCLUSIONS

The recent identification of CB₁ allosteric modulators indicated a new approach for developing safer therapeutics based on regulating the pharmacologically important CB₁ receptor. Unlike CB₁ orthosteric ligands, which typically present undesired psychotropic and psychiatric side effects, allosteric modulators hold promise as therapeutics with lesser side effects. This is because allosteric modulation of the receptor can be more finely regulated. Furthermore, some allosteric modulators may utilize biased signaling pathways such that signal transduction is more pathway-specific. In contrast to CB₁ orthosteric ligands, the structural diversity of CB₁ allosteric modulators is fairly limited. This work identified novel lead compounds from the biphenyl ureas that possess a pyrimidine ring in their structures. The new compounds bearing a pyrimidine moiety showed biological activities comparable to the well-established CB₁ allosteric modulator **2** that has a pyridine moiety. The two new scaffolds (i.e., **7** and **8**) offered broader opportunity for structural optimization due to the chemical nature of pyrimidine ring. Collectively, the newly identified pyrimidinyl biphenyl urea analogues provide new chances for the development of novel and potent CB₁ allosteric modulators. Additionally, the bias exhibited by these allosteric modulators for β -arrestin mediated signaling can confer selective fine-tuning of CB₁-impacted pathways.³⁹ In many other GPCRs, β -arrestin biased ligands have been shown to have therapeutically relevant benefits. Carvedilol (($\pm$)-[3-(9*H*-carbazol-4-yloxy)-2-hydroxypropyl][2-(2-methoxyphenoxy)-ethyl]amine), for example, is a β -arrestin biased ligand for both β_1 AR and β_2 AR which acts as an antagonist for G-protein mediated signaling and promotes β -arrestin mediated signaling that promotes epidermal growth factor transactivation to confer cardioprotection.⁴⁰ Thus, biased CB₁ allosteric modulators offer unique opportunities to develop therapeutics.

EXPERIMENTAL SECTION

Compounds

The compound **2** was purchased from Tocris Bioscience. All other tested compounds were synthesized in our synthetic laboratory at Texas A&M University.

Synthesis

All chemical reagents and solvents were purchased from Sigma-Aldrich Chemical Co. unless specified otherwise and used without further purification. All anhydrous reactions were performed under a static argon atmosphere in dried glassware using anhydrous solvents. Organic phases in work up were dried over anhydrous Na₂SO₄ and removed by evaporation under reduced pressure. The crude compounds were purified by a Combiflash R_f chromatography system (Teledyne Technologies, Inc., Thousand Oaks, CA) unless specified otherwise. Purities of the intermediates were established by several analytical methods including thin-layer chromatography (TLC), melting point, ¹H NMR, and mass spectrometry. Analytical thin-layer chromatography (TLC) was run on precoated silica gel

TLC aluminum plates (Whatman, UV₂₅₄, layer thickness 250 μm), and the chromatograms were visualized under ultraviolet (UV) light. Melting points were determined on a capillary electrothermal melting point apparatus and are uncorrected. ¹H NMR spectra of some intermediates and all final compounds were recorded on a Bruker Avance DPX-300 spectrometer operating at 300 MHz. The 2D ¹H NMR data of some intermediates were recorded on a Bruker Ascend-600 spectrometer operating at 600 MHz. All NMR spectra were recorded using CDCl₃ or DMSO-*d*₆ as solvent unless otherwise specified. The chemical shifts are reported in ppm (parts per million) relative to tetramethylsilane (TMS) as an internal standard. Multiplicities are indicated as brs (broad singlet), s (singlet), d (doublet), t (triplet), q (quartet), m (multiplets), dt (doublet of triplets), and ddd (doublet of doublets), and coupling constants (*J*) are reported in hertz (Hz). Low and high resolution mass spectra were obtained at either the Laboratory for Biological Mass Spectrometry of Texas A&M University for the APCI ionization method or at the School of Chemical Sciences, University of Illinois at Urbana–Champaign for the ESI ionization method. The purities of biologically tested compounds were analyzed either by combustion elemental analysis performed in Roberson Microlit Laboratories (Madison, NJ) or by the combination of HRMS and HPLC. The results of combustion elemental analysis indicated by the symbols of the elements were within $\pm 0.4\%$ of the calculated values for the proposed formula. The purity of each tested compound was determined to be greater than 95% either by combustion elemental analyses (C, H, N) or by HPLC with two different mobile phase systems.

General Procedure A: Preparation of Biphenyl Ureas (14a–14f and 8a–8t)—To the solution of 0.5 mmol of amine **12** (for synthesis of **14a–14f**) or amine **19** (for synthesis of **8a–8t**) in anhydrous dichloromethane (5–8 mL) was added the selected isocyanate **13** (0.75–0.95 mmol, 1.2–1.9 equiv) at 0 °C. The reaction mixture was stirred at 0 °C for 10 min and then at room temperature for 2 h. The reaction was monitored by TLC (30% acetone in hexane or 50–70% ethyl acetate in hexane). After completion of the reaction, if white suspension was formed, it was filtered. The filtered solid was washed with dichloromethane (2 mL) and diethyl ether (5 mL) successively and then dried in vacuum oven. If no solid was precipitated out upon the completion of the reaction, the reaction mixture was condensed in vacuo. The resultant crude compound was purified by Combiflash chromatography (0 to 50–80% ethyl acetate in hexane) to obtain the pyrimidinyl biphenyl urea compounds **14a–14f** and **8a–8t**.

General Procedure B: Preparation of Pyrimidinyl Biphenyl Ureas 7a–7d—To the solution of biphenyl urea **14** (0.1 mmol) in anhydrous tetrahydrofuran (2–10 mL), pyrrolidine (7–13 equiv) was added dropwise at room temperature. The reaction mixture was refluxed for 2–4 h. The progress of reaction was monitored by TLC (40% acetone in hexane). Upon completion of the reaction, the mixture was cooled to room temperature and condensed under reduced pressure. The residue was purified by Combiflash chromatography to obtain the target compounds **7a–7d**.

General Procedure C: Preparation of Pyrimidinyl Biphenyl Ureas 7e–7h—To the solution of biphenyl urea **14** (0.3 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (2–10 mL)

in a pressure tube was added dimethylamine (2–10 equiv, 2.0 M in methanol) at room temperature. The reaction mixture was refluxed for 2–4 h. The progress of the reaction was monitored by TLC (50% ethyl acetate in hexane). Upon completion of the reaction, it was cooled to room temperature and condensed under reduced pressure. The residue was partitioned between water (15 mL) and ethyl acetate (3 × 10 mL). The organic layer was separated and was washed with water and brine and dried over anhydrous Na₂SO₄. Filtration and removal of the solvent under reduced pressure provided the crude compound, which was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to obtain the desired compounds **7e–7h**.

1-(4-Chlorophenyl)-3-(3-(2-(pyrrolidine-1-yl)pyrimidine-4-yl)-phenyl)urea (7a): The compound **7a** was prepared from the biphenyl urea **14a** (28 mg, 0.078 mmol) and pyrrolidine (76 mg, 1.06 mmol) in anhydrous THF (2 mL) according to the general procedure B. The crude product was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to provide product **7a** (14 mg, 46%) as a white solid; mp 171–174 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.87 (d, *J* = 3.9 Hz, 2H), 8.41 (d, *J* = 4.8 Hz, 1H), 8.18 (s, 1H), 7.73–7.64 (m, 2H), 7.52–7.32 (m, 5H), 7.07 (d, *J* = 5.1 Hz, 1H), 3.58 (s, 4H), 1.96 (s, 4H). MS (ESI): *m/z* = 394.1 [M + H]⁺, 396.1 [M + H + 2]⁺. Anal. Calcd for (C₂₁H₂₀N₅OCl): C, 64.04; H, 5.12; N, 17.78. Found: C, 63.89; H, 5.37; N, 17.42.

1-(4-Bromophenyl)-3-(3-(2-(pyrrolidine-1-yl)pyrimidine-4-yl)-phenyl)urea (7b): The compound **7b** was prepared from the biphenyl urea **14b** (40 mg, 0.1 mmol) and pyrrolidine (83 mg, 1.2 mmol) according to the general procedure B. The product was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to provide product **7b** (19 mg, 47%) as a white solid; mp 180–183 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.87 (d, *J* = 3.6 Hz, 2H), 8.40 (d, *J* = 5.1 Hz, 1H), 8.17 (s, 1H), 7.72 (d, *J* = 7.5 Hz, 1H), 7.66 (d, *J* = 8.1 Hz, 1H), 7.45–7.38 (m, 5H), 7.07 (d, *J* = 4.8 Hz, 1H), 3.57 (s, 4H), 1.96 (s, 4H). MS (ESI): *m/z* = 438.1 [M + H]⁺, 440.1 [M + H + 2]⁺. Anal. Calcd for (C₂₁H₂₀N₅OBr·H₂O): C, 56.39; H, 4.73; N, 15.66. Found: C, 56.46; H, 4.35; N, 15.50.

1-(4-Fluorophenyl)-3-(3-(2-(pyrrolidine-1-yl)pyrimidine-4-yl)-phenyl)urea (7c): The compound **7c** was prepared from the biphenyl urea **14c** (0.12 g, 0.35 mmol) and pyrrolidine (0.17 g, 2.45 mmol) in anhydrous THF (12 mL) according to the general procedure B. The crude product was isolated by Combiflash chromatography (0–50% ethyl acetate in hexane) to yield **7c** (98 mg, 74%) as a white solid; mp 206–208 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.84 (s, 1H), 8.75 (s, 1H), 8.40 (d, *J* = 5.1 Hz, 1H), 8.17 (s, 1H), 7.71–7.64 (m, 2H), 7.50–7.38 (m, 3H), 7.16–7.06 (m, 3H), 3.57 (s, 4H), 1.96 (s, 4H). MS (ESI): *m/z* = 378.2 [M + H]⁺. Anal. Calcd for (C₂₁H₂₀FN₅O·¹/₄H₂O): C, 66.04; H, 5.41; N, 18.34. Found: C, 66.16; H, 5.34; N, 18.12.

1-(4-Cyanophenyl)-3-(3-(2-(pyrrolidine-1-yl)pyrimidine-4-yl)-phenyl)urea (7d): The compound **7d** was prepared from the biphenyl urea **14d** (30 mg, 0.085 mmol) and pyrrolidine (84 mg, 1.18 mmol) in anhydrous THF (2 mL) according to the general procedure B. The crude product was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to obtain product **7d** (17 mg, 51%) as a white solid; mp 153–156 °C. ¹H

NMR (300 MHz, DMSO- d_6): δ 9.25 (s, 1H), 9.03 (s, 1H), 8.41 (d, J = 5.1 Hz, 1H), 8.19 (s, 1H), 7.76–7.64 (m, 6H), 7.43 (t, J = 7.9 Hz, 1H), 7.08 (d, J = 5.1 Hz, 1H), 3.58 (s, 4H), 1.96 (s, 4H). MS (ESI): m/z = 385.2 $[M + H]^+$. Anal. Calcd for (C₂₂H₂₀N₆O·H₂O): C, 65.66; H, 5.51; N, 20.88. Found: C, 65.51; H, 5.26; N, 20.76.

1-(3-(2-(Dimethylamino)pyrimidin-4-yl)phenyl)-3-(4-fluorophenyl)urea (7e): The compound **7e** was prepared from the biphenyl urea **14c** (0.1 g, 0.3 mmol) and dimethylamine (1 mL, 2.0 mmol, 2.0 M in MeOH) in anhydrous THF (10 mL) according to the general procedure C. The crude product was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to obtain product **7e** (80 mg, 78%) as a white solid; mp 182–184 °C. ¹H NMR (300 MHz, DMSO- d_6): δ 8.85 (s, 1H), 8.76 (s, 1H), 8.42 (d, J = 5.1 Hz, 1H), 8.19 (t, J = 1.8 Hz, 1H), 7.72–7.69 (m, 1H), 7.66–7.63 (m, 1H), 7.50–7.38 (m, 3H), 7.16–7.07 (m, 3H), 3.21 (s, 6H). MS (ESI): m/z = 352.1 $[M + H]^+$. Anal. Calcd for (C₁₉H₁₈FN₅O): C, 64.95; H, 5.16; N, 19.93. Found: C, 64.85; H, 5.26; N, 19.79.

1-(4-Cyanophenyl)-3-(3-(2-(dimethylamino)pyrimidin-4-yl)-phenyl)urea (7f): The compound **7f** was prepared from the biphenyl urea **14d** (0.10 g, 0.286 mmol) and dimethylamine (0.275 mL, 0.55 mmol, 2.0 M in MeOH) in anhydrous THF (10 mL) according to the general procedure C. The crude product was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to provide **7f** (0.069 g, 67.6%) as a white solid; mp 132–134 °C. ¹H NMR (300 MHz, DMSO- d_6): δ 9.27 (s, 1H), 9.05 (s, 1H), 8.42 (d, J = 5.1 Hz, 1H), 8.22 (t, J = 1.8 Hz, 1H), 7.77–7.73 (m, 3H), 7.67–7.63 (m, 3H), 7.43 (t, J = 7.8 Hz, 1H), 7.09 (d, J = 5.1 Hz, 1H), 3.21 (s, 6H). MS (ESI): m/z = 359.2 $[M + H]^+$. Anal. Calcd for (C₂₀H₁₈N₆O·1/2H₂O): C, 65.38; H, 5.21; N, 22.87. Found: C, 65.75; H, 4.99; N, 22.58.

1-(3-(2-(Dimethylamino)pyrimidin-4-yl)phenyl)-3-(4-iodophenyl)-urea (7g): The compound **7g** was prepared from the biphenyl urea **14e** (0.10 g, 0.22 mmol) and dimethylamine (1.2 mL, 2.4 mmol, 2.0 M in MeOH) in anhydrous THF (15 mL) according to the general procedure C. The crude product was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to provide **7g** (35 mg, 35%) as a white solid; mp 230–232 °C. ¹H NMR (300 MHz, DMSO- d_6): δ 8.89 (s, 1H), 8.85 (s, 1H), 8.42 (d, J = 5.1 Hz, 1H), 8.19 (s, 1H), 7.73–7.59 (m, 4H), 7.44–7.31 (m, 3H), 7.08 (d, J = 5.1 Hz, 1H), 3.21 (s, 6H). MS (ESI): m/z = 460.1 $[M + H]^+$. Anal. Calcd for (C₁₉H₁₈IN₅O): C, 49.69; H, 3.95; N, 15.25. Found: C, 50.01; H, 4.02; N, 14.81.

1-(3-(2-(Dimethylamino)pyrimidin-4-yl)phenyl)-3-(3-fluorophenyl)urea (7h): The compound **7h** was prepared from the biphenyl urea **14f** (0.12 g, 0.35 mmol) and dimethylamine (1.22 mL, 2.44 mmol, 2.0 M in MeOH) in anhydrous THF (15 mL) according to the general procedure C. The crude compound was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to provide **7h** (0.10 g, 81%) as a white solid; mp 195–198 °C. ¹H NMR (300 MHz, DMSO- d_6): δ 8.98 (s, 1H), 8.94 (s, 1H), 8.42 (d, J = 5.1 Hz, 1H), 8.20 (s, 1H), 7.74–7.64 (m, 2H), 7.53–7.28 (m, 3H), 7.16–7.08 (m, 2H), 6.83–6.76 (m, 1H), 3.21 (s, 6H). MS (ESI): m/z = 352.2 $[M + H]^+$. Anal. Calcd for (C₁₉H₁₈FN₅O): C, 64.95; H, 5.16; N, 19.93. Found: C, 64.91; H, 5.27; N, 19.72.

1-(4-Chlorophenyl)-3-(3-(4-(pyrrolidin-1-yl)pyrimidin-2-yl)-phenyl)urea (8a): The title compound **8a** was synthesized from 3-(4-(pyrrolidine-1-yl)pyrimidin-2-yl)aniline **19a** (0.07 g, 0.29 mmol) and 4-chlorophenyl isocyanate **13a** (0.044 g, 0.29 mmol) in anhydrous CH₂Cl₂ (5 mL) according to the general procedure A. The crude compound was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to yield the product **8a** (0.085 g, 74.5%) as a white solid; mp 192–195 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.88 (s, 1H), 8.83 (s, 1H), 8.38 (s, 1H), 8.26 (d, *J* = 6.3 Hz, 1H), 7.97 (d, *J* = 7.8 Hz, 1H), 7.62 (d, *J* = 8.1 Hz, 1H), 7.50 (d, *J* = 8.7 Hz, 2H), 7.40–7.32 (m, 3H), 6.44 (d, *J* = 6.0 Hz, 1H), 3.61 (brs, 2H), 3.33 (brs, 2H), 1.98 (s, 4H). MS (ESI): *m/z* = 394.2 [M + H]⁺, 396.1 [M + H + 2]⁺. Anal. Calcd for (C₂₁H₂₀N₅OCl·¹/₃H₂O): C, 63.08; H, 5.21; N, 17.51. Found: C, 63.20; H, 5.38; N, 17.15.

1-(4-Bromophenyl)-3-(3-(4-(pyrrolidin-1-yl)pyrimidin-2-yl)-phenyl)urea (8b): The title compound **8b** was synthesized from 3-(4-(pyrrolidine-1-yl)pyrimidin-2-yl)aniline **19a** (0.07 g, 0.3 mmol) and 4-bromo phenyl isocyanate **13b** (0.086 g, 0.43 mmol) in anhydrous CH₂Cl₂ (5 mL) according to the general procedure A. The crude compound was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to yield product **8b** (0.105 g, 82.6%) as a white solid; mp 223–225 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.85 (s, 1H), 8.79 (s, 1H), 8.39 (s, 1H), 8.25 (d, *J* = 6.0 Hz, 1H), 7.97 (d, *J* = 7.8 Hz, 1H), 7.62 (d, *J* = 8.1 Hz, 1H), 7.46 (s, 4H), 7.36 (t, *J* = 7.8 Hz, 1H), 6.42 (d, *J* = 6.0 Hz, 1H), 3.62 (brs, 2H), 3.39 (brs, 2H), 1.98 (s, 4H). MS (ESI): *m/z* = 438.1 [M + H]⁺, 440.1 [M + H + 2]⁺. Anal. Calcd for (C₂₁H₂₀N₅OBr): C, 57.54; H, 4.60; N, 15.98. Found: C, 57.73; H, 4.53; N, 15.78.

1-(4-Fluorophenyl)-3-(3-(4-(pyrrolidin-1-yl)pyrimidin-2-yl)-phenyl)urea (8c): The title compound **8c** was synthesized from 3-(4-(pyrrolidine-1-yl)pyrimidin-2-yl)aniline **19a** (0.075 g, 0.31 mmol) and 4-fluorophenyl isocyanate **13c** (0.051 g, 0.37 mmol) in anhydrous CH₂Cl₂ (5 mL) according to the general procedure A. The white suspension was filtered. The solid was washed with dichloromethane (3 mL), then dried in vacuum oven to yield the compound **8c** (0.079 g, 67%) as a white solid; mp 185–187 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.80 (s, 1H), 8.68 (s, 1H), 8.39 (s, 1H), 8.26 (d, *J* = 6.0 Hz, 1H), 7.97 (d, *J* = 7.8 Hz, 1H), 7.62 (d, *J* = 8.1 Hz, 1H), 7.50–7.46 (m, 2H), 7.36 (t, *J* = 7.8 Hz, 1H), 7.13 (t, *J* = 9.0 Hz, 2H), 6.42 (d, *J* = 6.0 Hz, 1H), 3.64 (brs, 2H), 3.39 (brs, 2H), 1.99 (s, 4H). HRMS (ESI) *m/z* for C₂₁H₂₁FN₅O [M + H]⁺: calcd, 378.1730; found, 378.1727.

1-(4-Cyanophenyl)-3-(3-(4-(pyrrolidin-1-yl)pyrimidin-2-yl)-phenyl)urea (8d): The compound **8d** was synthesized from 3-(4-(pyrrolidine-1-yl)pyrimidin-2-yl)aniline **19a** (0.07 g, 0.3 mmol) and 4-cyanophenyl isocyanate **13d** (0.05 g, 0.36 mmol) in anhydrous CH₂Cl₂ (5 mL) according to the general procedure A. The crude compound was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to yield the title compound **8d** (0.064 g, 57.6%) as a white solid; mp 219–221 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.19 (s, 1H), 9.0 (s, 1H), 8.42 (s, 1H), 8.26 (d, *J* = 6.0 Hz, 1H), 8.0 (d, *J* = 7.5 Hz, 1H), 7.76–7.73 (d, *J* = 8.4 Hz, 2H), 7.67–7.62 (m, 3H), 7.39 (t, *J* = 7.9 Hz, 1H), 6.42 (d, *J* = 6.0 Hz, 1H), 3.61 (brs, 2H), 3.39 (brs, 2H), 1.98 (s, 4H). MS (ESI): *m/z* = 385.2 [M + H]⁺. Anal. Calcd for (C₂₂H₂₀N₆O): C, 68.73; H, 5.24; N, 21.86. Found: C, 68.59; H, 5.46; N, 21.51.

1-(3-(4-(Dimethylamino)pyrimidin-2-yl)phenyl)-3-(4-fluorophenyl)urea (8e): The title compound **8e** was prepared from amine **19b** (0.1 g, 0.47 mmol) and 4-fluorophenyl isocyanate **13c** (0.076 g, 0.55 mmol) as described in the general procedure A. The crude compound was purified by Combiflash chromatography (0–80% ethyl acetate in hexane) to yield the compound **8e** (0.127 g, 78%) as a white solid; mp 202–205 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.82 (s, 1H), 8.69 (s, 1H), 8.41 (t, *J* = 1.8 Hz, 1H), 8.28 (d, *J* = 6.3 Hz, 1H), 7.99–7.96 (dt, *J* = 7.8 Hz, 1.2 Hz, 1H), 7.64–7.60 (m, 1H), 7.51–7.46 (m, 2H), 7.37 (t, *J* = 7.8 Hz, 1H), 7.13 (t, *J* = 9.0 Hz, 2H), 6.62 (d, *J* = 6.0 Hz, 1H), 3.16 (s, 6H). MS (ESI): *m/z* = 352.1 [M + H]⁺. Anal. Calcd for (C₁₉H₁₈FN₅O): C, 64.95; H, 5.16; N, 19.93. Found: C, 64.68; H, 5.31; N, 19.86.

1-(4-Cyanophenyl)-3-(3-(4-(dimethylamino)pyrimidin-2-yl)-phenyl)urea (8f): The title compound **8f** was prepared from the amine **19b** (0.1 g, 0.47 mmol) and 4-cyanophenyl isocyanate **13d** (0.08 g, 0.56 mmol) as described in the general procedure A. The crude compound was purified by Combiflash chromatography (0–80% ethyl acetate in hexane) to yield the title compound **8f** (0.133 g, 79.6%) as a white solid; mp 146–149 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.20 (s, 1H), 9.02 (s, 1H), 8.44 (s, 1H), 8.28 (d, *J* = 6.0 Hz, 1H), 8.0 (d, *J* = 7.8 Hz, 1H), 7.76–7.73 (m, 2H), 7.67–7.61 (m, 3H), 7.39 (t, *J* = 7.8 Hz, 1H), 6.62 (d, *J* = 6.3 Hz, 1H), 3.16 (s, 6H). MS (ESI): *m/z* = 359.1 [M + H]⁺. Anal. Calcd for (C₂₀H₁₈N₆O·H₂O): C, 63.82; H, 5.36; N, 22.33. Found: C, 63.91; H, 5.27; N, 22.18.

1-(3-(4-(Dimethylamino)pyrimidin-2-yl)phenyl)-3-(4-iodophenyl)-urea (8g): The title compound **8g** was prepared from the amine **19b** (75 mg, 0.35 mmol) and 4-iodophenyl isocyanate **13e** (0.15 g, 0.61 mmol) as described in the general procedure A. The crude compound was purified by Combiflash chromatography (0–60% ethyl acetate in hexane) to yield the compound **8g** (0.112 g, 70%) as a white solid; mp 230–232 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.85 (s, 1H), 8.77 (s, 1H), 8.41 (s, 1H), 8.28 (d, *J* = 6.3 Hz, 1H), 8.0 (d, *J* = 7.8 Hz, 1H), 7.63–7.59 (m, 3H), 7.39–7.31 (m, 3H), 6.61 (d, *J* = 6.0 Hz, 1H), 3.15 (s, 6H). MS (ESI): *m/z* = 460.1 [M + H]⁺. Anal. Calcd for (C₁₉H₁₈IN₅O): C, 49.69; H, 3.95; N, 15.25. Found: C, 49.69; H, 3.90; N, 15.02.

1-(3-(4-(Dimethylamino)pyrimidin-2-yl)phenyl)-3-(3-fluorophenyl)urea (8h): The title compound **8h** was prepared from the amine **19b** (45 mg, 0.21 mmol) and 3-fluorophenyl isocyanate **13f** (35 mg, 0.26 mmol) as described in the general procedure A. The crude compound was purified by Combiflash chromatography (0–70% ethyl acetate in hexane) to yield the compound **8h** (44 mg, 60%) as a white solid; mp 116–119 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.89 (s, 2H), 8.42 (s, 1H), 8.28 (d, *J* = 6.3 Hz, 1H), 8.0 (d, *J* = 7.8 Hz, 1H), 7.62 (d, *J* = 8.1 Hz, 1H), 7.54–7.48 (m, 1H), 7.40–7.27 (m, 2H), 7.15 (d, *J* = 8.1 Hz, 1H), 6.82–6.76 (m, 1H), 6.62 (d, *J* = 6.0 Hz, 1H), 3.16 (s, 6H). HRMS (ESI) *m/z* for C₁₉H₁₉FN₅O [M + H]⁺: calcd, 352.1574; found, 352.1571.

1-(3-(4-(Pyrrolidin-1-yl)pyrimidin-2-yl)phenyl)-3-(4-(trifluoromethyl)phenyl)urea (8i): The title compound **8i** was synthesized from 3-(4-(pyrrolidine-1-yl)pyrimidin-2-yl)aniline **19a** (70 mg, 0.29 mmol) and the commercially available 4-(trifluoromethyl)phenyl isocyanate **13g** (98 mg, 0.52 mmol) in anhydrous CH₂Cl₂ (8 mL) according to the general

procedure A. Upon completion of reaction, the solution was filtered to obtain the white solid (TLC: R_f = 0.15, 70% ethyl acetate in hexane) after washed with ether (5 mL), dichloromethane (3 mL). The solid was dried in vacuum oven to yield the title compound **8i** (70 mg, 56%) as a white solid; mp 185–188 °C. ^1H NMR (300 MHz, DMSO- d_6): δ 9.09 (s, 1H), 8.95 (s, 1H), 8.42 (s, 1H), 8.26 (d, J = 6.0 Hz, 1H), 8.0 (d, J = 7.8 Hz, 1H), 7.70–7.62 (m, 5H), 7.38 (t, J = 7.9 Hz, 1H), 6.43 (d, J = 6.0 Hz, 1H), 3.65 (brs, 2H), 3.39 (brs, 2H), 1.98 (s, 4H). MS (ESI): m/z = 428.2 $[\text{M} + \text{H}]^+$. Anal. Calcd for ($\text{C}_{22}\text{H}_{20}\text{F}_3\text{N}_5\text{O}$): C, 61.82; H, 4.72; N, 16.39. Found: C, 61.49; H, 4.66; N, 16.28.

1-(4-Acetylphenyl)-3-(3-(4-(pyrrolidin-1-yl)pyrimidin-2-yl)phenyl)-urea (8j): The compound **8j** was synthesized from 3-(4-(pyrrolidine-1-yl)pyrimidin-2-yl)aniline **19a** (70 mg, 0.29 mmol) and the commercially available 4-acetylphenyl isocyanate **13h** (84 mg, 0.52 mmol) in anhydrous CH_2Cl_2 (8 mL) according to the general procedure A. The crude compound was purified by Combiflash chromatography (0–70% ethyl acetate in hexane) to yield the compound **8j** (30 mg, 25%) as an off-white solid; mp 163–166 °C. ^1H NMR (300 MHz, DMSO- d_6): δ 9.10 (s, 1H), 8.96 (s, 1H), 8.42 (s, 1H), 8.26 (d, J = 6.0 Hz, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.93 (d, J = 8.4 Hz, 2H), 7.65–7.59 (m, 3H), 7.38 (t, J = 7.9 Hz, 1H), 6.43 (d, J = 6.0 Hz, 1H), 3.65 (brs, 2H), 3.35 (brs, 2H), 2.52 (s, 3H), 1.98 (s, 4H). HRMS (ESI) m/z for $\text{C}_{23}\text{H}_{24}\text{N}_5\text{O}_2$ $[\text{M} + \text{H}]^+$: calcd, 402.1930; found, 402.1920.

Ethyl 4-(3-(3-(4-(Pyrrolidin-1-yl)pyrimidin-2-yl)phenyl)ureido)-benzoate (8k): The title compound **8k** was synthesized from 3-(4-(pyrrolidine-1-yl)pyrimidin-2-yl)aniline **19a** (70 mg, 0.29 mmol) and ethyl 4-isocyanatobenzoate **13i** (100 mg, 0.52 mmol) in anhydrous CH_2Cl_2 (8 mL) according to the general procedure A. Upon completion of reaction, the suspension was filtered to afford the white solid (TLC: R_f = 0.3, 80% ethyl acetate in hexane), which was washed with dichloromethane (5 mL). The solid was dried in vacuum oven to yield the title compound **8k** (80 mg, 64%) as a white solid; mp 116–119 °C. ^1H NMR (300 MHz, DMSO- d_6): δ 9.09 (s, 1H), 8.95 (s, 1H), 8.42 (s, 1H), 8.26 (d, J = 6.0 Hz, 1H), 8.0 (d, J = 7.5 Hz, 1H), 7.9 (d, J = 8.4 Hz, 2H), 7.65–7.60 (m, 3H), 7.38 (t, J = 7.9 Hz, 1H), 6.43 (d, J = 6.0 Hz, 1H), 4.28 (q, J = 7.2 Hz, 6.9 Hz, 2H), 3.65 (brs, 2H), 3.35 (brs, 2H), 1.98 (s, 4H), 1.31 (t, J = 7.0 Hz, 3H). MS (ESI): m/z = 432.2 $[\text{M} + \text{H}]^+$. Anal. Calcd for ($\text{C}_{24}\text{H}_{25}\text{N}_5\text{O}_3 \cdot 1/4\text{H}_2\text{O}$): C, 66.12; H, 5.90; N, 16.06. Found: C, 65.85; H, 5.80; N, 15.89.

4-(3-(3-(4-(Pyrrolidin-1-yl)pyrimidin-2-yl)phenyl)ureido)benzoic Acid (8l): To a solution of compound **8k** (55 mg, 0.127 mmol) in methanol (1 mL) and THF (2 mL) was added the solution of lithium hydroxide monohydrate (64 mg, 1.53 mmol) in 2 mL of water at room temperature. The reaction mixture was stirred overnight. The reaction was monitored by TLC (50% acetone in hexane). Upon completion of reaction, the solution was acidified with 2 N HCl to pH 5. The white solid formed was filtered and washed with water (2 mL) and hexane. The solid was dried in vacuum oven to obtain the title compound **8l** (35 mg, 68%) as a white solid; mp 221–223 °C. ^1H NMR (300 MHz, DMSO- d_6): δ 12.64 (brs, 1H), 9.66 (s, 1H), 9.55 (s, 1H), 8.38 (s, 1H), 8.29 (d, J = 7.2 Hz, 1H), 7.88 (d, J = 8.7 Hz, 3H), 7.76–7.72 (m, 1H), 7.60–7.49 (m, 3H), 6.76 (d, J = 7.2 Hz, 1H), 3.78 (brs, 2H), 3.58 (brs, 2H), 2.03 (brs, 4H). HRMS (ESI) m/z for $\text{C}_{22}\text{H}_{22}\text{N}_5\text{O}_3$ $[\text{M} + \text{H}]^+$: calcd, 404.1723; found, 404.1716.

1-(4-Methoxyphenyl)-3-(3-(4-(pyrrolidin-1-yl)pyrimidin-2-yl)-phenyl)urea (8m): The compound **8m** was synthesized from 3-(4-(pyrrolidin-1-yl)pyrimidin-2-yl)aniline **19a** (70 mg, 0.29 mmol) and 4-methoxyphenyl isocyanate **13j** (78 mg, 0.52 mmol) in anhydrous CH₂Cl₂ (8 mL) according to the general procedure A. Upon completion of reaction, the suspension was filtered to obtain the white solid (TLC: *R*_f = 0.2, 70% ethyl acetate in hexane), which was washed with dichloromethane (5 mL). The solid was dried in a vacuum oven to provide compound **8m** (83 mg, 73%) as a white solid; mp 219–221 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.72 (s, 1H), 8.44 (s, 1H), 8.37 (s, 1H), 8.25 (d, *J* = 5.7 Hz, 1H), 7.95 (d, *J* = 7.8 Hz, 1H), 7.63 (d, *J* = 8.4 Hz, 1H), 7.39–7.32 (m, 3H), 6.87 (d, *J* = 8.4 Hz, 2H), 6.42 (d, *J* = 6.0 Hz, 1H) 3.72 (s, 3H), 3.64 (brs, 2H), 3.35 (brs, 2H), 1.98 (s, 4H). MS (ESI): *m/z* = 390.2 [M + H]⁺. Anal. Calcd for (C₂₂H₂₃N₅O₂·¹/₄H₂O): C, 67.07; H, 6.01; N, 17.78. Found: C, 66.90; H, 6.05; N, 17.72.

1-(4-Hydroxyphenyl)-3-(3-(4-(pyrrolidin-1-yl)pyrimidin-2-yl)-phenyl)urea (8n): To the suspension of compound **8m** (0.6 g, 0.15 mmol) in 20 mL of CH₂Cl₂, BBr₃ (1.65 mL, 1.65 mmol, 1.0 M in hexane) was added at 0 °C. The mixture was stirred overnight at room temperature. The reaction was monitored by TLC. Upon completion of the reaction, 10 mL of water was slowly added to quench the reaction. The reaction mixture was treated with saturated Na₂CO₃ aqueous solution to pH 9. Then it was condensed in vacuo to remove CH₂Cl₂. The residue was extracted with ethyl acetate (3 × 10 mL). The organic layer was separated and washed with water and brine and dried over Na₂SO₄. Filtration and removal of solvent provided the crude product, which was purified by Combiflash chromatography (0–10% methanol in dichloromethane) to yield **8n** (23 mg, 41%) as a white solid; mp 229–231 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.08 (s, 1H), 8.68 (s, 1H), 8.36–8.24 (m, 3H), 7.94 (d, *J* = 7.8 Hz, 1H), 7.62 (d, *J* = 8.1 Hz, 1H), 7.34 (t, *J* = 7.8 Hz, 1H), 7.23 (d, *J* = 8.7 Hz, 2H), 6.70 (d, *J* = 8.7 Hz, 2H), 6.42 (d, *J* = 5.7 Hz, 1H), 3.61 (brs, 2H), 3.39 (brs, 2H), 1.97 (s, 4H). HRMS (ESI) *m/z* for C₂₁H₂₂N₅O₂ [M + H]⁺: calcd, 376.1773; found, 376.1771.

1-(3-Cyanophenyl)-3-(3-(4-(pyrrolidin-1-yl)pyrimidin-2-yl)-phenyl)urea (8o): The compound **8o** was synthesized from 3-(4-(pyrrolidin-1-yl)pyrimidin-2-yl)aniline **19a** (0.1 g, 0.42 mmol) and 3-cyanophenyl isocyanate **13k** (0.089 g, 0.62 mmol) in 5 mL of anhydrous dichloromethane according to the general procedure A. The crude compound was purified by Combiflash chromatography (0–70% ethyl acetate in hexane) to yield title compound **8o** (0.08 g, 50%) as a white solid; mp 203–205 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.01 (d, *J* = 5.4 Hz, 2H), 8.41 (t, *J* = 1.8 Hz, 1H), 8.26 (d, *J* = 6.0 Hz, 1H), 8.01–7.98 (m, 2H), 7.71–7.67 (m, 1H), 7.64–7.61 (m, 1H), 7.53–7.35 (m, 3H), 6.43 (d, *J* = 6.0 Hz, 1H), 3.66 (brs, 2H), 3.40 (brs, 2H), 1.99 (s, 4H). HRMS (ESI) *m/z* for C₂₂H₂₁N₆O [M + H]⁺: calcd, 385.1777; found, 385.1774.

1-(3-(4-(Azetidin-1-yl)pyrimidin-2-yl)phenyl)-3-(4-cyanophenyl)-urea (8p): The compound **8p** was prepared from 3-(4-(azetidin-1-yl)pyrimidin-2-yl)benzenamine **19g** (148.8 mg, 0.66 mmol) and 4-isocyanatobenzonitrile **13d** (109.8 mg, 0.72 mmol) according to the general procedure A. The crude compound was purified by Combiflash chromatography (0–80% ethyl acetate in hexane) to afford the product **8p** (210.4 mg,

86.37%) as a white solid; mp 140–143 °C. ¹H NMR (300 MHz, CDCl₃): δ 9.18 (s, 1H), 9.02 (s, 1H), 8.37–8.36 (m, 1H), 8.27 (d, *J* = 5.8 Hz, 1H), 7.96 (d, *J* = 7.7 Hz, 1H), 7.74 (d, *J* = 8.8 Hz, 2H), 7.66–7.61 (m, 3H), 7.38 (t, *J* = 7.9 Hz, 1H), 6.31 (d, *J* = 6.0 Hz, 1H), 4.10 (t, *J* = 7.5 Hz, 4H), 2.40 (t, *J* = 7.7 Hz, 2H). HRMS (ESI) *m/z* for C₂₁H₁₉N₆O [M + H]⁺: calcd, 371.1620; found, 371.1620.

1-(4-Cyanophenyl)-3-(3-(4-(piperidin-1-yl)pyrimidin-2-yl)phenyl)-urea (8q): The compound **8q** was prepared from amine **19e** (80 mg, 0.31 mmol) and 4-cyanophenyl isocyanate **13d** (54 mg, 0.37 mmol) in anhydrous dichloromethane (8 mL) according to the general procedure A. The crude compound was purified by Combiflash chromatography (0–70% ethyl acetate in hexane) to yield the title compound **8q** (95 mg, 76%) as a white solid; mp 120–123 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.20 (s, 1H), 9.03 (s, 1H), 8.36 (t, *J* = 1.5 Hz, 1H), 8.27 (d, *J* = 6.3 Hz, 1H), 7.99–7.96 (dt, *J* = 9.0 Hz, 1.2 Hz, 1H), 7.75 (m, 2H), 7.67–7.64 (m, 3H), 7.39 (t, *J* = 7.8 Hz, 1H), 6.76 (d, *J* = 6.3 Hz, 1H), 3.73 (s, 4H), 1.67 (s, 2H), 1.57 (s, 4H). MS (ESI): *m/z* = 399.2 [M + H]⁺. Anal. Calcd for (C₂₃H₂₂N₆O·H₂O): C, 66.33; H, 5.81; N, 20.18. Found: C, 66.63; H, 5.61; N, 19.68.

1-(4-Cyanophenyl)-3-(3-(4-(diethylamino)pyrimidin-2-yl)phenyl)-urea (8r): The compound **8r** was synthesized from amine **19d** (80 mg, 0.33 mmol) and 4-cyanophenyl isocyanate **13d** (57 mg, 0.40 mmol) in anhydrous dichloromethane (8 mL) as described in the general procedure A. The crude compound was purified by Combiflash chromatography (0–70% ethyl acetate in hexane) to yield the product **8r** (80 mg, 63%) as a white solid; mp 139–141 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.20 (s, 1H), 9.02 (s, 1H), 8.42 (t, *J* = 1.5 Hz, 1H), 8.25 (d, *J* = 6.0 Hz, 1H), 7.99–7.96 (m, 1H), 7.76–7.73 (d, *J* = 9.0 Hz, 2H), 7.67–7.64 (d, *J* = 9.0 Hz, 2H), 7.62–7.61 (m, 1H), 7.40 (t, *J* = 7.9 Hz, 1H), 6.58 (d, *J* = 6.3 Hz, 1H), 3.59 (brs, 4H), 1.18 (t, *J* = 7.0 Hz, 6H). MS (ESI): *m/z* = 387.2 [M + H]⁺. Anal. Calcd for (C₂₂H₂₂N₆O·H₂O): C, 65.33; H, 5.98; N, 20.78. Found: C, 65.04; H, 5.78; N, 20.71.

1-(4-Cyanophenyl)-3-(3-(4-(ethyl(methyl)amino)pyrimidin-2-yl)-phenyl)urea (8s): The compound **8s** was synthesized from the amine **19c** (60 mg, 0.26 mmol) and 4-cyanophenyl isocyanate **13d** (45 mg, 0.31 mmol) in anhydrous dichloromethane (8 mL) according to the general procedure A. The crude compound was purified by Combiflash chromatography (0–70% ethyl acetate in hexane) to yield the product **8s** (62 mg, 64%) as a white solid; mp 120–123 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.20 (s, 1H), 9.02 (s, 1H), 8.42 (t, *J* = 1.6 Hz, 1H), 8.27 (d, *J* = 6.0 Hz, 1H), 8.0–7.97 (dt, *J* = 7.8 Hz, 1.4 Hz, 1H), 7.75 (d, *J* = 8.7 Hz, 2H), 7.67 (d, *J* = 9.0 Hz, 2H), 7.61 (m, 1H), 7.39 (t, *J* = 7.8 Hz, 1H), 6.60 (d, *J* = 6.3 Hz, 1H), 3.65 (brs, 2H), 3.11 (s, 3H), 1.15 (t, *J* = 7.0 Hz, 3H). MS (ESI): *m/z* = 373.2077 [M + H]⁺. Anal. Calcd for (C₂₁H₂₀N₆O·H₂O): C, 64.60; H, 5.68; N, 21.52. Found: C, 64.48; H, 5.58; N, 21.50.

1-(4-Cyanophenyl)-3-(3-(4-(cyclopropylamino)pyrimidin-2-yl)-phenyl)urea (8t): The compound **8t** was prepared from the amine **19f** (80 mg, 0.35 mmol) and 4-cyanophenyl isocyanate **13d** (61 mg, 0.42 mmol) in anhydrous dichloromethane (8 mL) according to the general procedure A. The crude compound was purified by Combiflash chromatography (0–70% ethyl acetate in hexane) to yield the product **8t** (87 mg, 67%) as a white solid; mp 180–

182 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.19 (s, 1H), 9.0 (s, 1H), 8.44 (t, *J* = 1.5 Hz, 1H), 8.28 (brs, 1H), 7.97 (d, *J* = 7.5 Hz, 1H), 7.76–7.73 (d, *J* = 9.0 Hz, 2H), 7.66–7.64 (m, 3H), 7.56 (d, *J* = 7.2 Hz, 1H), 7.38 (t, *J* = 7.9 Hz, 1H), 6.55 (brs, 1H), 2.66 (brs, 1H), 0.82–0.75 (m, 2H), 0.55–0.49 (m, 2H). MS (ESI): *m/z* = 371.2 [M + H]⁺. Anal. Calcd for (C₂₁H₁₈N₆O·1/2H₂O): C, 66.48; H, 5.05; N, 22.15. Found: C, 66.21; H, 5.01; N, 21.72.

2-Chloro-4-(3-nitrophenyl)pyrimidine (11): In a pressure tube, argon gas was bubbled through a mixture of the boronic acid **10** (0.672 g, 4.0 mmol), 2,4-dichloropyrimidine **9** (0.50 g, 3.4 mmol), Na₂CO₃ (1.07 g, 10.1 mmol), 1.5 mL of water, and 15 mL of dimethoxyethane for 20 min. The catalyst Pd(PPh₃)₄ (387 mg, 0.34 mmol) was added to the reaction mixture. Then the mixture was saturated with argon gas for 5 min and heated in the pressure tube for 7 h at 90 °C. It was then cooled to room temperature and filtered through a Celite padded funnel. The filtrate was mixed with water (15 mL) and extracted with ethyl acetate (2 × 20 mL). The combined organic layer was washed with water and brine and then dried over Na₂SO₄. Filtration and removal of solvent under reduced pressure provided the crude product, which was purified by chromatography (0–30% ethyl acetate in hexane) to afford 0.350 g (43.8%) of target compound **11** as off-white solid; mp 138–141 °C. ¹H NMR (600 MHz, CDCl₃): δ 8.93 (t, *J* = 2.1 Hz, 1H, H8), 8.77 (d, *J* = 5.2 Hz, 1H, H6), 8.49 (ddd, *J* = 7.9 Hz, 1.5 Hz, 1.0 Hz, 1H, H10), 8.41 (ddd, *J* = 8.4 Hz, 2.3 Hz, 1.1 Hz, 1H, H12), 7.77–7.73 (m, 2H, H5 and H11). MS (ESI): *m/z* = 236.0 [M + H]⁺. The ¹H NMR data were in agreement with the reported data.⁴¹

3-(2-Chloropyrimidin-4-yl)aniline (12): To the solution of compound **11** (1.38 g, 5.87 mmol) in anhydrous dichloromethane (20 mL) and methanol (20 mL) was added stannous chloride dihydrate (6.23 g, 27.6 mmol) at 0 °C. The reaction mixture was then stirred at rt overnight. The reaction was monitored by TLC (30% acetone in hexane). After completion of the reaction, solvents were removed under reduced pressure. Saturated Na₂CO₃ aqueous solution (20 mL) was added to the residue. The suspension was filtered. The filtrate was extracted with ethyl acetate twice (2 × 20 mL). The organic phase was separated and washed with water and brine and dried over Na₂SO₄. Filtration and removal of solvent under reduced pressure provided the crude product, which was purified by Combiflash chromatography (0–40% ethyl acetate in hexane) to afford 0.48 g (40%) of amine **12** as yellow solid; mp 137–140 °C. ¹H NMR (300 MHz, CDCl₃): δ 8.61 (d, *J* = 5.1 Hz, 1H), 7.60 (d, *J* = 5.4 Hz, 1H), 7.48 (t, *J* = 1.9 Hz, 1H), 7.40–7.37 (ddd, *J* = 7.8 Hz, 1.5 Hz, 1.2 Hz, 1H), 7.31–7.26 (m, 1H), 6.87–6.83 (m, 1H), 3.86 (s, 2H). MS (ESI): *m/z* = 206.0 [M + H]⁺.

1-(4-Chlorophenyl)-3-(3-(2-chloropyrimidin-4-yl)phenyl)urea (14a): The biphenyl urea **14a** was synthesized from 3-(2-chloropyrimidin-4-yl)aniline **12** (0.06 g, 0.29 mmol) and 4-chlorophenyl isocyanate **13a** (0.067 g, 0.43 mmol) in 5 mL of CH₂Cl₂ according to the general procedure A. The crude product was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to yield **14a** (40 mg, 40%) as a white solid; mp 227–229 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.05 (s, 1H), 8.85–8.82 (m, 2H), 8.33 (s, 1H), 8.09 (d, *J* = 5.4 Hz, 1H), 7.81–7.78 (d, *J* = 7.8 Hz, 1H), 7.69–7.66 (m, 1H), 7.53–7.46 (m, 3H), 7.35 (s, 1H), 7.32 (s, 1H). MS (ESI): *m/z* = 359.0 [M + H]⁺, 361.0 [M + H + 2]⁺.

1-(4-Bromophenyl)-3-(3-(2-chloropyrimidin-4-yl)phenyl)urea (14b): The biphenyl urea **14b** was synthesized from 3-(2-chloropyrimidin-4-yl)aniline **12** (0.07 g, 0.34 mmol) and 4-bromophenyl isocyanate **13b** (0.1 g, 0.5 mmol) in 5 mL of CH₂Cl₂ according to the general procedure A. The crude product was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to provide **14b** (55 mg, 41%) as a white solid; mp 235–237 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.08 (s, 1H), 8.88 (s, 1H), 8.83 (d, *J* = 5.4 Hz, 1H), 8.34 (s, 1H), 8.09 (d, *J* = 5.1 Hz, 1H), 7.80 (d, *J* = 7.8 Hz, 1H), 7.67 (d, *J* = 8.1 Hz, 1H), 7.51–7.46 (m, 5H). MS (ESI): *m/z* = 403.0 [M + H]⁺, 405.0 [M + H + 2]⁺.

1-(3-(2-Chloropyrimidin-4-yl)phenyl)-3-(4-fluorophenyl)urea (14c): The biphenylurea **14c** was synthesized from 3-(2-chloropyrimidin-4-yl)aniline **12** (0.1 g, 0.49 mmol) and 4-fluorophenyl isocyanate **13c** (0.12 g, 0.88 mmol) in 10 mL of CH₂Cl₂ according to the general procedure A. The crude product was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) and yielded **14c** (0.145 g, 86.7%) as a white solid; mp 223–225 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.00 (s, 1H), 8.83 (d, *J* = 5.4 Hz, 1H), 8.73 (s, 1H), 8.33 (t, *J* = 1.8 Hz, 1H), 8.08 (d, *J* = 5.4 Hz, 1H), 7.80 (d, *J* = 8.1 Hz, 1H), 7.69–7.66 (m, 1H), 7.51–7.46 (m, 3H), 7.17–7.11 (t, *J* = 9.0 Hz, 2H). MS (ESI): *m/z* = 343.1 [M + H]⁺, 345.1 [M + H + 2]⁺.

1-(3-(2-Chloropyrimidin-4-yl)phenyl)-3-(4-cyanophenyl)urea (14d): The biphenyl urea **14d** was synthesized from 3-(2-chloropyrimidin-4-yl)aniline **12** (0.1 g, 0.49 mmol) and 4-cyanophenyl isocyanate **13d** (84 mg, 0.58 mmol) in 5 mL of CH₂Cl₂ according to the general procedure A. The crude product was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to yield **14d** (120 mg, 70%) as a white solid; mp 237–239 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.24 (s, 1H), 9.20 (s, 1H), 8.83 (d, *J* = 5.1 Hz, 1H), 8.34 (s, 1H), 8.09 (d, *J* = 5.1 Hz, 1H), 7.83–7.65 (m, 6H), 7.51 (t, *J* = 7.9 Hz, 1H). MS (ESI): *m/z* = 350.1 [M + H]⁺, 352.1 [M + H + 2]⁺.

1-(3-(2-Chloropyrimidin-4-yl)phenyl)-3-(4-iodophenyl)urea (14e): The biphenyl urea **14e** was synthesized from 3-(2-chloropyrimidin-4-yl)aniline **12** (0.07 g, 0.34 mmol) and 4-iodophenyl isocyanate **13e** (0.125 g, 0.51 mmol) in 5 mL of CH₂Cl₂ according to the general procedure A. The crude product was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to yield **14e** (0.11 g, 71%) as a white solid; mp 226–229 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.04 (s, 1H), 8.83 (d, *J* = 5.1 Hz, 2H), 8.33 (t, *J* = 1.6 Hz, 1H), 8.09 (d, *J* = 5.4 Hz, 1H), 7.80 (d, *J* = 8.1 Hz, 1H), 7.68–7.65 (m, 1H), 7.63–7.60 (m, 2H), 7.51–7.46 (m, 1H), 7.33 (d, *J* = 8.7 Hz, 2H). MS (ESI): *m/z* = 451.0 [M + H]⁺, 453.0 [M + H + 2]⁺.

1-(3-(2-Chloropyrimidin-4-yl)phenyl)-3-(3-fluorophenyl)urea (14f): The biphenyl urea **14f** was synthesized from 3-(2-chloropyrimidin-4-yl)aniline **12** (0.12 g, 0.59 mmol) and 3-fluorophenyl isocyanate **13f** (0.144 g, 1.1 mmol) in CH₂Cl₂ (15 mL) according to the general procedure A. The crude product was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to yield product **14f** (150 mg, 75%) as a white solid; mp 216–219 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.08 (s, 1H), 8.94 (s, 1H), 8.83 (d, *J* = 5.1 Hz, 1H), 8.33 (t, *J* = 1.8 Hz, 1H), 8.09 (d, *J* = 5.4 Hz, 1H), 7.82–7.79 (m, 1H), 7.70–7.67 (m, 1H),

7.54–7.47 (m, 2H), 7.36–7.29 (m, 1H), 7.19–7.14 (m, 1H), 6.84–6.78 (m, 1H). MS (ESI): $m/z = 343.1$ $[M + H]^+$, 345.1 $[M + H + 2]^+$.

2-Chloro-4-(pyrrolidine-1-yl)pyrimidine (16a) and 4-Chloro-2-(pyrrolidin-1-yl)pyrimidine (17a): To the solution of 2,4-dichloropyrimidine **3** (4 g, 26.8 mmol) in anhydrous THF (35 mL), pyrrolidine **15a** (3.82 g, 53.69 mmol) was added dropwise at 0 °C. The reaction mixture was stirred at rt for 2 h. The reaction was monitored by TLC (30% ethyl acetate in hexane). Upon completion of the reaction, solvent was removed under reduced pressure. The crude compound was purified by column chromatography (0–30% ethyl acetate in hexane) to yield 2-chloro-4-(pyrrolidine-1-yl)pyrimidine **16a** ($R_f = 0.5$, 3.8 g, 77.3%) as a white solid and 4-chloro-2-(pyrrolidin-1-yl)pyrimidine **17a** ($R_f = 0.75$, 800 mg, 16%) as a white solid. **16a**: mp 111–114 °C. ^1H NMR (300 MHz, CDCl_3): 7.98 (d, $J = 6.0$ Hz, 1H), 6.18 (d, $J = 6.0$ Hz, 1H), 3.63 (brs, 2H), 3.34 (brs, 2H), 2.05–2.00 (brs, 4H). MS (ESI): $m/z = 184.1$ $[M + H]^+$, 186.1 $[M + H + 2]^+$. **17a**: mp 65–67 °C. ^1H NMR (300 MHz, CDCl_3): δ 8.16 (d, $J = 5.1$ Hz, 1H), 6.47 (d, $J = 5.1$ Hz, 1H), 3.57 (t, $J = 6.3$ Hz, 4H), 1.99 (s, 4H). MS (ESI): $m/z = 184.1$ $[M + H]^+$, 186.1 $[M + H + 2]^+$. The ^1H NMR data of **16a** and **17a** were in agreement with the reported data.⁴²

2-Chloro-N,N-dimethylpyrimidine-4-amine (16b) and 4-Chloro-N,N-dimethylpyrimidin-2-amine (17b): 2,4-Dichloropyrimidine **9** (1.5 g, 10.068 mmol) was dissolved in dimethylamine **15b** (15 mL, 30 mmol, 2.0 M in MeOH). The reaction mixture was stirred at room temperature for 2 h and monitored by TLC (**16b**, $R_f = 0.17$; **17b**, $R_f = 0.77$, 30% ethyl acetate in hexane). Upon completion of the reaction, the solvent was removed under reduced pressure. Then 10 mL of water was added to the residue and the organic products were extracted with ethyl acetate (3×10 mL). The combined organic layer was washed with water and brine and dried over Na_2SO_4 . Filtration and removal of solvent in vacuo provided the crude product, which was purified by Combiflash chromatography (0–30% ethyl acetate in hexane) to yield 2-chloro-*N,N*-dimethylpyrimidine-4-amine **16b** as a white solid (1.26 g, 80%) and 4-chloro-*N,N*-dimethylpyrimidine-2-amine **17b** as a white solid (100 mg, 9.5%). **16b**: mp 71–73 °C. ^1H NMR (300 MHz, CDCl_3): δ 8.01 (d, $J = 6.0$ Hz, 1H), 6.31 (d, $J = 6.0$ Hz, 1H), 3.12 (s, 6H). MS (ESI): $m/z = 158.0$ $[M + H]^+$. **17b**: mp 33–35 °C. ^1H NMR (300 MHz, CDCl_3): δ 8.15 (d, $J = 5.1$ Hz, 1H), 6.47 (d, $J = 5.1$ Hz, 1H), 3.18 (s, 6H). MS (ESI): $m/z = 158.0$ $[M + H]^+$. Their ^1H NMR data were in agreement with the reported data.^{43,44}

2-Chloro-N-ethyl-N-methylpyrimidin-4-amine (16c) and 4-Chloro-N-ethyl-N-methylpyrimidin-2-amine (17c): 2,4-Dichloropyrimidine **9** (2.5 g, 16.78 mmol) was dissolved in anhydrous THF (25 mL) under argon atmosphere. *N*-Methylethanamine **15c** (1.56 mL, 17.07 mmol) was added to the reaction mixture at room temperature. The mixture was stirred at room temperature for 2 h. The reaction was monitored by TLC (**16c**, $R_f = 0.3$; **17c**, $R_f = 0.83$, 60% hexane in ethyl acetate). Upon completion of the reaction, the solution was diluted with 50 mL of dichloromethane. The mixture was treated with 30 mL of saturated NaHCO_3 aqueous solution to pH = 9. The aqueous layer was extracted with ethyl acetate twice. The organic phase was separated and dried over anhydrous magnesium sulfate. Filtration and removal of the solvent afforded the crude product, which was purified

by Combiflash chromatography (0–30% ethyl acetate in hexane) to obtain the product 2-chloro-*N*-ethyl-*N*-methylpyrimidin-4-amine **16c** (1.70 g, 59%) as a colorless liquid and 4-chloro-*N*-ethyl-*N*-methylpyrimidin-2-amine **17c** (0.414g, 14.4%) as a colorless liquid.

16c: ^1H NMR (300 MHz, CDCl_3): δ 7.99 (dd, $J = 6.2, 1.3$ Hz, 1H), 6.30 (d, $J = 6.2$ Hz, 1H), 3.56 (brs, 2H), 3.07 (s, 3H), 1.18 (t, $J = 7.1$ Hz, 3H). MS (APCI): m/z 171.8 $[\text{M} + \text{H}]^+$.

17c: ^1H NMR (300 MHz, CDCl_3): δ 8.14 (d, $J = 5.1$ Hz, 1H), 6.45 (d, $J = 5.0$ Hz, 1H), 3.66 (dd, $J = 7.1$ Hz, 2H), 3.13 (s, 3H), 1.17 (t, $J = 7.1$ Hz, 3H). MS (APCI): $m/z = 171.8$ $[\text{M} + \text{H}]^+$. The ^1H NMR data of the two isomers were in agreement with the data reported in the literature.⁴⁴

2-Chloro-*N,N*-diethylpyrimidin-4-amine (16d) and 4-Chloro-*N,N*-diethylpyrimidin-2-amine (17d):

2,4-Dichloropyridimidine **9** (2.5 g, 16.78 mmol) was added to diethylamine **15d** (10 mL, 96.68 mmol) at room temperature under argon. The reaction was stirred for 30 min. The reaction was monitored by TLC (**16d**, $R_f = 0.43$; **17d**, $R_f = 0.9$, 60% hexane in ethyl acetate). Upon completion of the reaction, the solution was diluted with 100 mL of ethyl acetate. Filtration and removal of the solvent afforded the crude product, which was purified by Combiflash chromatography (0–30% ethyl acetate in hexane) to obtain the product 2-chloro-*N,N*-diethylpyrimidin-4-amine **16d** (2.085 g, 67%) as a colorless liquid and 4-chloro-*N,N*-diethylpyrimidin-2-amine **17d** (0.414g, 0.87%) as a colorless liquid.

16d: ^1H NMR (300 MHz, CDCl_3): δ 7.97 (d, $J = 6.3$ Hz, 1H), 6.28 (d, $J = 6.3$ Hz, 1H), 3.85–3.14 (brs, 4H), 1.20 (t, $J = 7.1$ Hz, 6H). MS (APCI): $m/z = 185.8$ $[\text{M} + \text{H}]^+$. **17d**: ^1H NMR of (300 MHz, CDCl_3): 8.13 (d, $J = 4.8$ Hz, 1H), 6.44 (d, $J = 4.8$ Hz, 1H), 3.60 (dd, $J = 7.2, 6.9$ Hz, 4H), 1.18 (t, $J = 7.2$ Hz, 6H). MS (APCI): $m/z = 185.85$ $[\text{M} + \text{H}]^+$. The ^1H NMR data of the two isomers were in agreement with the reported data.⁴⁵

2-Chloro-4-(piperidin-1-yl) pyrimidine (16e) and 4-Chloro-2-(piperidin-1-yl)pyrimidine (17e):

2,4-Dichloropyridimidine **9** (2.5 g, 16.78 mmol) was dissolved in anhydrous 1,4-dioxane (16 mL) under argon. Triethylamine (2.33 mL, 16.78 mmol) was added dropwise to the reaction mixture at room temperature. Piperidine **15e** (1.56 mL, 17.081 mmol) was added dropwise into the reaction mixture, which was cooled with a cold water bath. The reaction mixture was stirred at room temperature for 3 h. The reaction was monitored by TLC (**16e**, $R_f = 0.23$; **17e**, $R_f = 0.80$, 60% ethyl acetate in hexane). Upon completion of the reaction, removal of solvent under reduced pressure afforded the crude product, which was purified by Combiflash chromatography (0–30% ethyl acetate in hexane) to yield the product 2-chloro-4-(piperidin-1-yl)pyrimidine **16e** (2.40 g, 72.4%) as a white solid, mp 81–83 °C, and 4-chloro-2-(piperidin-1-yl)pyrimidine **17e** (0.62 g, 18.77%) as a yellow solid, mp 45–47 °C. **16e**: ^1H NMR (300 MHz, CDCl_3): δ 7.99 (d, $J = 6.0$ Hz, 1H), 6.37 (d, $J = 6.0$ Hz, 1H), 3.62 (s, 4H), 1.79–1.47 (m, 6H). MS (APCI): $m/z = 197.8$ $[\text{M} + \text{H}]^+$. **17e**: ^1H NMR (300 MHz, CDCl_3): δ 8.13 (d, $J = 5.1$ Hz, 1H), 6.43 (d, $J = 5.1$ Hz, 1H), 3.77 (t, $J = 5.2$ Hz, 4H), 1.80–1.44 (m, 6H). MS (APCI): $m/z = 197.8$ $[\text{M} + \text{H}]^+$. The ^1H NMR data of **16e** and **17e** were in agreement with the reported data.⁴⁶

2-Chloro-*N*-cyclopropylpyrimidin-4-amine (16f) and 4-Chloro-*N*-cyclopropylpyrimidin-2-amine (17f):

2,4-Dichloropyridimidine **9** (2.5 g, 16.78 mmol) was dissolved in anhydrous 1,4-dioxane (25 mL) under argon. Triethylamine (3.5 mL, 25.17

mmol) was added dropwise into the reaction mixture at room temperature. Cyclopropanamine **15f** (1.2 mL, 16.78 mmol) was added dropwise to the reaction mixture, which was cooled with a cold water bath. The reaction mixture was stirred at room temperature overnight. It was monitored by TLC (**16f**, R_f = 0.22; **17f**, R_f = 0.41, 60% hexane in ethyl acetate). Upon completion of the reaction, the solvent was removed under reduced pressure to afford the crude product, which was partitioned between 50 mL of dichloromethane and 20 mL of water. The organic layer was separated, and the aqueous phase was extracted with dichloromethane twice. The combined organic layer was washed with water and brine and dried over anhydrous Na_2SO_4 . Filtration and removal of solvent in vacuo provided the crude product, which was purified by Combiflash chromatography (0–30% ethyl acetate in hexane) to obtain the product 2-chloro-*N*-cyclopropylpyrimidin-4-amine **16f** (1.81 g, 63.7%) as a white solid, mp 126–128 °C, and 4-chloro-*N*-cyclopropylpyrimidin-2-amine **17f** (0.643 g, 22.7%) as a yellow solid, mp 80–83 °C. **16f**: ^1H NMR (600 MHz, CDCl_3): δ 8.14 (d, J = 5.8 Hz, 1H, H6), 6.61 (d, J = 5.8 Hz, 1H, H5), 5.84 (s, 1H, H7), 2.57 (s, 1H, H8), 0.90–0.87 (m, 2H, H9 and H10), 0.63–0.61 (m, 2H, H9 and H10). MS (ESI): m/z = 170.1 $[\text{M} + \text{H}]^+$. **17f**: ^1H NMR (600 MHz, CDCl_3): δ 8.20 (d, J = 5.2 Hz, 1H, H6), 6.61 (d, J = 5.2 Hz, 1H, H5), 5.59 (s, 1H, H7), 2.80–2.77 (m, 1H, H8), 0.87–0.83 (m, 2H, H9 and H10), 0.56–0.55 (m, 2H, H9 and H10). MS (ESI): m/z = 170.1 $[\text{M} + \text{H}]^+$. The structures of **16f** and **17f** were assigned by their 2D ^1H NMR data (see Supporting Information, Figures S6 and S9).

4-(Azetidin-1-yl)-2-chloropyrimidine (16g) and 2-(Azetidin-1-yl)-4-chloropyrimidine (17g):

2,4-Dichloropyrimidine **9** (5.21 g, 35.03 mmol) was dissolved in anhydrous methanol (53 mL) under argon. Triethylamine (5.1 mL, 36.78 mmol) was added into the reaction mixture at room temperature. Azetidine **15g** (2.3 mL, 35.03 mmol) was added dropwise into the reaction mixture, which was cooled with a cold water bath. The reaction mixture was stirred at room temperature overnight. The reaction was monitored by TLC (**16g**, R_f = 0.14; **17g**, R_f = 0.39, 60% hexane in ethyl acetate). Upon completion of the reaction, removal of solvent in vacuo afforded a residue, which was partitioned between 50 mL of dichloromethane and 20 mL of water. The organic layer was separated, and the aqueous phase was extracted with dichloromethane twice. The combined organic layer was washed with water and brine and dried over anhydrous Na_2SO_4 . Filtration and removal of solvent provided the crude product, which was purified by Combiflash chromatography (0–30% ethyl acetate in hexane) to afford the product 4-(azetidin-1-yl)-2-chloropyrimidine **16g** (2.755 g, 46.5%) as a white solid, mp 93–95 °C, and the 2-(azetidin-1-yl)-4-chloropyrimidine **17g** (0.63 g, 10.8%) as a white solid, mp 85–87 °C. **16g**: ^1H NMR (600 MHz, CDCl_3): δ 7.97 (d, J = 5.8 Hz, 1H, H6), 6.03 (d, J = 5.8 Hz, 1H, H5), 4.15 (brs, 4H, H8 and H10), 2.50–2.44 (m, 2H, H9). MS (ESI): m/z = 170.1 $[\text{M} + \text{H}]^+$. **17g**: ^1H NMR (600 MHz, CDCl_3): δ 8.14 (d, J = 5.2 Hz, 1H, H6), 6.51 (d, J = 5.2 Hz, 1H, H5), 4.18 (t, J = 7.8 Hz, 4H, H8 and H10), 2.41–2.36 (m, 2H, H9). MS (ESI): m/z = 170.1 $[\text{M} + \text{H}]^+$. The structures of **16g** and **17g** were assigned by their 2D ^1H NMR data (see Supporting Information, Figure S12 and S15).

2-(3-Nitrophenyl)-4-(pyrrolidin-1-yl)pyrimidine (18a): In a pressure tube, argon gas was bubbled through a mixture of 3-nitrophenylboronic acid **10** (0.68 g, 4.09 mmol), 2-chloro-4-amino-pyrimidine **16a** (0.5 g, 2.73 mmol), Na_2CO_3 (0.87 g, 8.18 mmol), 1,4-dioxane (12

mL), and H₂O (3 mL) for 20–25 min. Then catalyst Pd(PPh₃)₄ (315 mg, 0.27 mmol) was added, and the reaction mixture was refluxed overnight. Upon completion of the reaction, the mixture was allowed to cool to room temperature and was filtered through a small Celite pad. The filtrate was washed with water (20 mL), and the organic compound was extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with water and brine and dried over Na₂SO₄. Filtration and removal of solvent in vacuo provided the crude product, which was purified by Combiflash chromatography (0–30% ethyl acetate in hexane) to afford the compound **18a** (0.46 g, 62.4%) as a yellow solid; mp 147–149 °C. ¹H NMR (300 MHz, CDCl₃): δ 9.25 (s, 1H), 8.75 (d, *J* = 7.8 Hz, 1H), 8.28 (d, *J* = 6.0 Hz, 2H), 7.60 (t, *J* = 8.1 Hz, 1H), 6.26 (d, *J* = 6.0 Hz, 1H), 3.78 (brs, 2H), 3.41 (brs, 2H), 2.07 (s, 4H). MS (ESI): *m/z* = 271.1 [M + H]⁺.

N,N-Dimethyl-2-(3-nitrophenyl)pyrimidin-4-amine (18b): Argon gas was bubbled through the mixture of the commercially available 3-nitrophenylboronic acid **10** (0.637 g, 3.815 mmol), 2-chloro-*N,N*-dimethylpyrimidin-4-amine **16b** (0.5 g, 3.18 mmol), and Na₂CO₃ (1.012 g, 9.55 mmol) for 10 min. Then Pd(PPh₃)₄ (0.367 g, 0.317 mmol) was charged into the reaction vessel. The reaction was carried as described in the procedure for compound **18a**. The crude compound was purified by Combiflash chromatography (0–30% ethyl acetate in hexane) to yield compound **18b** (0.42 g, 64%) as a pale-yellow solid; mp 146–149 °C. ¹H NMR (300 MHz, CDCl₃): δ 9.25 (t, *J* = 1.9 Hz, 1H), 8.76–8.73 (dt, *J* = 7.8 Hz, 1.2 Hz, 1H), 8.32–8.26 (m, 2H), 7.61 (t, *J* = 7.8 Hz, 1H), 6.41 (d, *J* = 6.3 Hz, 1H), 3.22 (s, 6H). MS (ESI): *m/z* = 245.1 [M + H]⁺.

N-Ethyl-N-methyl-2-(3-nitrophenyl)pyrimidin-4-amine (18c): In a pressure tube, argon gas was bubbled through the mixture of 3-nitrophenylboronic acid **10** (1.181 g, 7.07 mmol), 2-chloro-*N*-ethyl-*N*-methylpyrimidin-4-amine **16c** (1.0 g, 5.89 mmol), and Na₂CO₃ (1.874 g, 17.68 mmol) in the mixture solvent of water (6.5 mL) and dimethoxyethane (26 mL) for 10 min. Then Pd(PPh₃)₄ (681 mg, 0.5893 mmol) catalyst was added to the mixture. The reaction mixture was refluxed in the pressure tube for 7 h. The reaction was monitored by TLC (30% acetone in hexane). Upon completion of the reaction, the mixture was cooled to room temperature and filtered through a short Celite pad. The filtrate was concentrated, and ethyl acetate was added. The solution was washed with water and brine and dried over anhydrous Na₂SO₄. Filtration and removal of the solvent provided the crude product, which was purified by Combiflash chromatography (0–30% ethyl acetate in hexane) to afford the title compound **18c** (0.788 g, 51.8%) as a yellow solid; mp 57–60 °C. ¹H NMR (300 MHz, CDCl₃): δ 9.24 (s, 1H), 8.74 (d, *J* = 7.8, 1.4 Hz, 1H), 8.37–8.19 (m, 2H), 7.61 (t, *J* = 7.9 Hz, 1H), 6.39 (d, *J* = 6.1 Hz, 1H), 3.69 (s, 2H), 3.17 (s, 3H), 1.25 (t, *J* = 7.1 Hz, 3H). MS (APCI): *m/z* = 258.9 [M + H]⁺.

N,N-Diethyl-2-(3-nitrophenyl)pyrimidin-4-amine (18d): Argon gas was bubbled through the mixture of the commercially available 3-nitrophenylboronic acid **10** (1.353 g, 8.1045 mmol), 2-chloro-*N,N*-diethylpyrimidin-4-amine **16d** (1.0 g, 5.403 mmol), and Na₂CO₃ (1.145 g, 10.806 mmol) in the mixture of water (10.8 mL) and 1,2-dimethoxyethane (25 mL) for 10 min. Then Pd(PPh₃)₄ (313 mg, 0.2702 mmol) was added to the reaction mixture. The reaction was carried through the procedure as described in the method for compound

18a. The crude compound was purified by Combiflash chromatography (0–30% ethyl acetate in hexane) to afford *N,N*-diethyl-2-(3-nitrophenyl)pyrimidin-4-amine **18d** (0.974 g, 66.2%) as a yellow solid; mp 65–67 °C. ¹H NMR (300 MHz, CDCl₃): δ 9.23 (s, 1H), 8.72 (d, *J* = 7.8 Hz, 1H), 8.28 (d, *J* = 6.6 Hz, 2H), 7.61 (t, *J* = 6.0 Hz, 1H), 6.37 (d, *J* = 8.0 Hz, 1H), 3.62 (s, 4H), 1.27 (t, *J* = 7.1 Hz, 6H). MS (APCI): *m/z* = 272.9 [M + H]⁺.

2-(3-Nitrophenyl)-4-(piperidin-1-yl)pyrimidine (18e): Argon gas was bubbled through the mixture of the commercially available 3-nitrophenylboronic acid **10** (1.271 g, 7.612 mmol), 2-chloro-4-(piperidin-1-yl)pyrimidine **16e** (1.0 g, 5.074 mmol), and Na₂CO₃ (1.076 g, 10.148 mmol) in the mixture of water (10.1 mL) and 1,2-dimethoxyethane (25 mL) for 10 min. Then Pd(PPh₃)₄ (313 mg, 0.2702 mmol) was added to the reaction mixture. The reaction was carried through the procedure as described in the method for compound **18a**. The crude compound was purified by flash column chromatography (0–30% ethyl acetate in hexane) to yield 2-(3-nitrophenyl)-4-(piperidin-1-yl)pyrimidine **18e** (0.664 g, 46.08%) as a yellow solid; mp 85–88 °C. ¹H NMR (300 MHz, CDCl₃): δ 9.22 (s, 1H), 8.73 (d, *J* = 7.5 Hz, 1H), 8.41–8.15 (m, 2H), 7.61 (t, *J* = 8.0 Hz, 1H), 6.48 (d, *J* = 6.3 Hz, 1H), 3.74 (s, 4H), 1.71 (m, 7H). MS (APCI): *m/z* = 285.0 [M + H]⁺.

N-Cyclopropyl-2-(3-nitrophenyl)pyrimidin-4-amine (18f): Argon gas was bubbled through the mixture of the commercially available 3-nitrophenylboronic acid **10** (1.482 g, 8.874 mmol), 2-chloro-*N*-cyclopropylpyrimidin-4-amine **16f** (1.0 g, 5.92 mmol), and Na₂CO₃ (1.254 g, 8.87 mmol) in the mixture of water (12.5 mL) and 1,2-dimethoxyethane (30 mL) for 10 min. Then Pd(PPh₃)₄ (684 mg, 0.5916 mmol) was added to the reaction mixture. The reaction was carried through the procedure as described in the method for compound **18a**. The crude product was purified by flash chromatography (0–30% ethyl acetate in hexane) to yield **18f** (1.434 g, 75.47%) as a yellow solid; mp 150–152 °C. ¹H NMR (300 MHz, CDCl₃): δ 9.20 (t, *J* = 2.0 Hz, 1H), 8.69 (dt, *J* = 7.9, 1.4 Hz, 1H), 8.42 (d, *J* = 6.0 Hz, 1H), 8.28 (ddd, *J* = 8.2, 2.4, 1.1 Hz, 1H), 7.60 (t, *J* = 8.0 Hz, 1H), 6.67 (d, *J* = 5.7 Hz, 1H), 5.53 (s, 1H), 2.63 (brs, 1H), 1.00–0.80 (m, 2H), 0.76–0.53 (m, 2H). MS (ESI): *m/z* = 257.1 [M + H]⁺.

4-(Azetidin-1-yl)-2-(3-nitrophenyl)pyrimidine (18g): Argon gas was bubbled through the mixture of the commercially available 3-nitrophenylboronic acid **10** (1.382 g, 8.2734 mmol), 4-(azetidin-1-yl)-2-chloropyrimidine **16g** (1.0 g, 5.916 mmol), and Na₂CO₃ (1.254 g, 11.8314 mmol) in the mixture solvent of water (12.5 mL) and 1,2-dimethoxyethane (30 mL) for 10 min. Then Pd(PPh₃)₄ (684 mg, 0.5916 mmol) was added to the reaction mixture. The reaction was carried through the procedure as described in the method for compound **18a**. The crude product was purified by Combiflash chromatography (0–30% ethyl acetate in hexane) to yield **18g** (0.779 g, 51.42%) as a yellow solid; mp 123–125 °C. ¹H NMR (300 MHz, CDCl₃): δ 9.22 (t, *J* = 1.5, 1H), 8.73 (dt, *J* = 7.8, 1.5 Hz, 1H), 8.48–8.17 (m, 2H), 7.60 (t, *J* = 8.0 Hz, 1H), 6.14 (d, *J* = 5.9 Hz, 1H), 4.20 (t, *J* = 7.6 Hz, 4H), 2.50 (m, 2H). MS (ESI): *m/z* = 257.1 [M + H]⁺.

3-(4-(Pyrrolidine-1-yl)pyrimidin-2-yl)aniline (19a): To the solution of compound **18a** (0.29 g, 1.073 mmol) in ethyl acetate (15 mL) was added a catalytic amount (5% equiv) of

10% Pd/C. The reaction mixture was stirred at room temperature under hydrogen atmosphere for 3–4 h. It was monitored by TLC. After the starting material was consumed, the reaction mixture was filtered through a small Celite pad. The filtrate was concentrated in vacuo. The crude product was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to obtain title compound **19a** (0.23 g, 90.5%) as an off-white solid; mp 158–161 °C. ¹H NMR (300 MHz, CDCl₃): δ 8.25 (d, *J* = 6.3 Hz, 1H), 7.82 (d, *J* = 7.8 Hz, 1H), 7.78 (s, 1H), 7.26–7.21 (m, 1H), 6.78 (d, *J* = 7.5 Hz, 1H), 6.20 (d, *J* = 6.3 Hz, 1H), 3.91–3.20 (brs, 6H), 2.04 (s, 4H). MS (ESI): *m/z* = 241.1 [M + H]⁺.

2-(3-Aminophenyl)-N,N-dimethylpyrimidine-4-amine (19b): To the solution of compound **18b** (0.35 g, 1.433 mmol) in ethyl acetate (30 mL) was added a catalytic amount (5% equiv) of 10% Pd/C. The reaction mixture was stirred at room temperature under hydrogen atmosphere for 3–4 h and monitored by TLC. After the starting material was consumed, the reaction mixture was filtered through a small Celite pad. The filtrate was concentrated in vacuo to afford the crude product, which was purified by Combiflash chromatography (0–50% ethyl acetate in hexane) to obtain pure amine **19b** (0.3 g, 97%) as an off-white solid; mp 137–140 °C. ¹H NMR (300 MHz, CDCl₃): δ 8.27 (d, *J* = 6.3 Hz, 1H), 7.84–7.80 (m, 1H), 7.76 (t, *J* = 1.8 Hz, 1H), 7.27–7.21 (m, 1H), 6.80–6.76 (m, 1H), 6.33 (d, *J* = 6.3 Hz, 1H), 4.73 (brs, 2H), 3.18 (s, 6H). MS (ESI): *m/z* = 215.1 [M + H]⁺.

2-(3-Aminophenyl)-N-ethyl-N-methylpyrimidin-4-amine (19c): To the solution of nitro compound **18c** (0.70 g, 2.712 mmol) in ethyl acetate (40 mL), a catalytic amount (5% equiv) of 10% Pd/C was added. The reaction mixture was stirred at room temperature under hydrogen atmosphere for 3–4 h. The reaction was monitored by TLC (70% ethyl acetate in hexane). After the starting material was consumed, the reaction mixture was filtered through a small Celite pad. The filtrate was concentrated in vacuo. The crude product was purified by Combiflash chromatography (0–70% ethyl acetate in hexane) to obtain pure amine **19c** (0.25 g, 38%) as a viscous pale-yellow gum. ¹H NMR (300 MHz, CDCl₃): δ 8.26 (d, *J* = 6.0 Hz, 1H), 7.83–7.80 (dt, *J* = 7.8 Hz, 1.3 Hz, 1H), 7.76–7.75 (dd, *J* = 3.6 Hz, 1.8 Hz, 1H), 7.26–7.21 (m, 1H), 6.79–6.75 (ddd, *J* = 7.8 Hz, 1.1 Hz, 1H), 6.31 (d, *J* = 6.0 Hz, 1H), 3.67 (d, *J* = 6.9 Hz, 2H), 3.13 (s, 3H), 1.22 (t, *J* = 7.2 Hz, 3H). MS (ESI): *m/z* = 229.1505 [M + H]⁺.

2-(3-Aminophenyl)-N,N-diethylpyrimidin-4-amine (19d): To the solution of nitro compound **18d** (0.35 g, 1.286 mmol) in ethyl acetate (20 mL), a catalytic amount (5% equiv) of 10% Pd/C was added. The reaction mixture was stirred at room temperature under hydrogen atmosphere for 4 h. It was monitored by TLC (70% ethyl acetate in hexane). After the starting material was consumed, the reaction mixture was filtered through a small Celite pad. The filtrate was concentrated in vacuo and was dried in vacuum oven to obtain amine **19d** (0.25 g, 80%) as a viscous pale-yellow gum. ¹H NMR (300 MHz, CDCl₃): δ 8.24 (d, *J* = 6.0 Hz, 1H), 7.82–7.79 (m, 1H), 7.75 (m, 1H), 7.26–7.22 (m, 2H), 6.79–6.75 (m, 1H), 6.29 (d, *J* = 6.3 Hz, 1H), 3.60 (m, 4H), 1.24 (t, *J* = 7.0 Hz, 6H). MS (ESI): *m/z* = 243.2 [M + H]⁺.

3-(4-(Piperidin-1-yl)pyrimidin-2-yl)benzenamine (19e): To the solution of nitro compound **19e** (0.45 g, 1.583 mmol) in ethyl acetate (20 mL), a catalytic amount (5% equiv)

of 10% Pd/C was added. The reaction mixture was stirred at room temperature under hydrogen atmosphere for 3–4 h. It was monitored by TLC (70% ethyl acetate in hexane). After the starting material was consumed, the reaction mixture was filtered through a small Celite pad. The filtrate was concentrated in vacuo. The crude product was purified by Combiflash chromatography (0–70% ethyl acetate in hexane) to obtain pure amine **19e** (0.36 g, 89%) as an off-white solid; mp 118–120 °C. ¹H NMR (300 MHz, CDCl₃): δ 8.25 (d, *J* = 6.3 Hz, 1H), 7.80–7.77 (m, 1H), 7.73 (m, 1H), 7.25–7.20 (m, 1H), 6.78–6.74 (m, 1H), 6.39 (d, *J* = 6.3 Hz, 1H), 3.70 (s, 6H), 1.66 (s, 6H). MS (ESI): *m/z* = 255.2 [M + H]⁺.

2-(3-Aminophenyl)-N-cyclopropylpyrimidin-4-amine (19f): To the solution of compound **18f** (0.5 g, 1.952 mmol) in ethyl acetate (30 mL), a catalytic amount (5% equiv) of 10% Pd/C was added. The reaction mixture was stirred at room temperature under hydrogen atmosphere for 12 h. It was monitored by TLC (70% ethyl acetate in hexane). Upon completion of reaction, the reaction mixture was filtered through a small Celite pad. The filtrate was concentrated in vacuo. The crude product was purified by Combiflash chromatography (0–70% ethyl acetate in hexane) to obtain pure amine **19f** (0.335 g, 76%) as a pale-yellow solid; mp 90–92 °C. ¹H NMR (300 MHz, CDCl₃): δ 8.38 (d, *J* = 6.0 Hz, 1H), 7.74–7.70 (m, 1H), 7.67 (m, 1H), 7.22 (d, *J* = 7.8 Hz, 1H), 6.79–6.75 (ddd, *J* = 7.8 Hz, 1.2 Hz, 1H), 6.60 (d, *J* = 6.0 Hz, 1H), 5.43 (brs, 1H), 2.58 (brs, 1H), 0.89–0.83 (m, 2H), 0.64–0.59 (m, 2H). MS (ESI): *m/z* = 227.1 [M + H]⁺.

3-(4-(Azetidin-1-yl)pyrimidin-2-yl)benzenamine (19g): 4-(Azetidin-1-yl)-2-(3-nitrophenyl)pyrimidine **18g** (200 mg, 0.78 mmol) was dissolved in 10 mL methanol. Then 100 mg of 10% Pd/C was added to the solution. The reaction mixture was stirred at room temperature for 1 h and was monitored by TLC. Upon complete consumption of the starting material, the solution was filtered. The filtration was evaporated under reduced pressure to afford the product **19g** (79.9 mg, 90.49%) as a white solid; mp 168–170 °C. ¹H NMR (300 MHz, CDCl₃): δ 8.22 (d, *J* = 5.8 Hz, 1H), 7.57 (t, *J* = 2.0 Hz, 1H), 7.49 (dt, *J* = 7.2, 1.2 Hz, 1H), 7.07 (t, *J* = 7.8 Hz, 1H), 6.64 (ddd, *J* = 7.9, 2.5, 1.1 Hz, 1H), 6.25 (d, *J* = 5.8 Hz, 1H), 5.14 (s, 2H), 4.07 (t, *J* = 7.5 Hz, 4H), 2.38 (m, 2H). MS (ESI): *m/z* = 227.1 [M + H]⁺.

Cell Line and Culture Conditions

Human embryonic kidney cells (HEK293T) was a kind gift from Dr. Randall Walikonis (Department of Physiology and Neurobiology, University of Connecticut). The cell line was cultured in DMEM medium with 10% FBS (v/v) and glucose (3.5 mg/mL). Cultures were maintained at 37 °C in humidified incubators with 5% CO₂/95% air.

CB₁ Expression and Membrane Preparation

HEK293T cells were seeded at approximately 800000 cells/100 mm dishes and transiently transfected using the calcium-phosphate precipitation method. Membrane preparation was made as described previously.⁴⁷ Briefly, 24 h post transfection, the cells were harvested and washed with phosphate buffered saline (PBS). The cells were resuspended in PBS containing mammalian protease inhibitor cocktail ((4-2-aminoethyl)benzene-sulfonyl fluoride, pepstatin A, E-64, bestatin, leupeptin, and aprotinin) (Sigma-Aldrich, St. Louis, MO) followed by lysis by nitrogen cavitation at 750 psi for 5 min using a Parr cell disruption

bomb. The cell lysate was spun at 500g for 10 min at 4 °C to remove nuclei, cell debris, and intact cells. The supernatant was collected and spun at 100000g for 45 min at 4 °C. The membrane containing pellet was resuspended in TME buffer (25 mM Tris-HCl, 5 mM MgCl₂, and 1 mM EDTA, pH 7.4) containing 7% w/v sucrose. The protein concentration was determined using Bradford assay.⁴⁸ The membrane preparation was then stored at – 70 °C.

Radioligand Binding Assay

To determine the allosteric parameters K_B and α , ligand binding assays were performed as previously described.³⁷ Membrane preparation expressing the CB₁ receptor was incubated with at least nine different concentrations (ranging between 100 pM and 100 μ M) of unlabeled allosteric compound in the presence of 0.5 nM [³H]CP55,940 (141.2 Ci/mmol, PerkinElmer Life Sciences (Boston, MA)), which is an orthosteric agonist of CB₁. TME containing 0.2% fatty acid free BSA was used as a buffer to make a final volume of 200 μ L. Nonspecific binding was determined by incubating the membranes with a high concentration of unlabeled CP55,940 (1 μ M). The reaction was terminated by adding 300 μ L of TME buffer containing 5% BSA and subsequent filtration through Whatman GF/C filter paper with a Brandel cell harvester. This was followed by washing with ice-cold TME buffer and collecting the filter paper sections corresponding to each sample. Radioactivity was measured using liquid scintillation counting.

[³⁵S]GTP γ S Evaluation

To evaluate the impact of the test compounds on the G-protein coupling efficiency of the CB₁ receptor, GTP γ S assays were performed as described previously.³⁰ Briefly, 7.5 μ g of membrane preparation expressing the CB₁ receptor was incubated with a saturating concentration of CP55,940 (1 μ M), 0.1 nM [³⁵S]GTP γ S (1250 Ci/mmol; PerkinElmer Life Sciences, Boston, MA), 5 μ M GDP (Sigma, St. Louis, MO), and 0.1% (w/v) BSA in the absence and presence of varying concentrations of the test allosteric modulators. GTP γ S binding assay buffer (50 mM Tris-HCl, pH 7.4, 3 mM MgCl₂, 0.2 mM EGTA, and 100 mM NaCl) was used to make a total volume of 200 μ L, and the membranes were incubated at 30 °C for an hour. Nonspecific binding was determined with 10 μ M unlabeled GTP γ S (Sigma, St. Louis, MO). For the controls, membrane preparations expressing CB₁ receptor were treated with DMSO or a high concentration of the inverse agonist SR141716A (1 μ M). Membrane preparations from the same cells not transfected with CB₁ were also evaluated for the G-protein coupling levels to determine non-CB₁ mediated GTP γ S binding. The reaction was terminated by filtration through Whatman GF/C filter papers followed by washing with cold TME buffer. The filter paper sections were collected and radioactivity was measured by liquid scintillation counting.

Data Analysis

All ligand binding and GTP γ S assays were carried out in duplicate, and at least three independent experiments were performed for each curve. For the ligand binding assays, data are presented as a mean with the corresponding 95% confidence limits. Data were analyzed by nonlinear regression using Prism 6.0 (Graphpad Software Inc., San Diego, CA) as previously described.³⁰

Immunoblotting Studies

Cells expressing CB₁ and siRNA targeting β -arrestin 1, β -arrestin 2, or nonsilencing RNA duplex were washed twice with PBS and treated with CP55,940 (0.5 μ M) or allosteric modulator **2** (10 μ M), **7d** (10 μ M), and **8d** (10 μ M) for 5 min. To determine if there is a G protein component to ERK1/2 phosphorylation, cells were treated with 5 ng/mL PTX for 12 h at 37 °C before compound treatment. Subsequently the cells were washed with ice-cold PBS and lysed with ice-cold lysis buffer (150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 7.5) plus protease inhibitor cocktail (4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), pepstain A, E-64, bestatin, leupeptin, and aprotinin; Sigma, St Louis, MO). Cell extracts were centrifuged at 18500g for 15 min at 4 °C and the supernatant stored at –20 °C. After heating at 95 °C for 3 min, 13 μ g of total protein was resolved by 10% SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membrane. After washing with blocking reagent (Fisher Scientific, Pittsburgh, PA), the membrane was incubated for 1 h at rt with the primary antibody (1:3000 phospho-p44/42 and p44/42 antibodies; Cell Signal Technology, Danvers, MA). The membrane was then washed with PBS and incubated with antirabbit peroxidase-conjugated secondary antibody (1:5000; Cell Signaling Technology, Danvers, MA) for 1 h at rt. Detection of reactive proteins employed the SuperSignal West Femto chemiluminescent substrate system (Thermo Fisher Scientific).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported in part by National Institutes of Health grant DA039942 (to D.A.K. and D.L.) and Faculty Development Fund of Texas A&M Health Science Center (to D.L.). We thank the Laboratory for Biological Mass Spectrometry of Texas A&M University for assistance obtaining mass data. We thank Dr. Kumar Kaluarachchi of the M.D. Anderson Cancer Center for help recording 2D NMR spectra.

ABBREVIATIONS USED

CB₁	cannabinoid receptor type 1
CB₂	cannabinoid receptor type 2
GPCR	G-protein coupled receptor
SAR	structure–activity relationship
[³⁵S]GTPγS	guanosine 5'-O-(3-[³⁵ S]-thio)triphosphate
ERK	extracellular signal-regulated kinases
cAMP	3'-5'-cyclic adenosine monophosphate
HEK293	human embryonic kidney 293 cells
BSA	bovine serum albumin

TME	Tris-Mg ²⁺ - EDTA
EGTA	ethylene glycol tetraacetic acid
PTX	pertussis toxin
SR141716A	5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl- <i>N</i> -(piperidin-1-yl)-1 <i>H</i> -pyrazole-3-carboxamide
CP55	940, 2-[(1 <i>R</i> ,2 <i>R</i> ,5 <i>R</i>)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol
APCI	atmospheric pressure chemical ionization
E-64	(1 <i>S</i> ,2 <i>S</i>)-2-(((<i>S</i>)-1-((4-guanidinobutyl)amino)-4-methyl-1-oxopentan-2-yl)carbamoyl)cyclopropane-carboxylic acid

References

1. Petrocellis LD, Cascio MG, Marzo VD. The endocannabinoid system: a general view and latest additions. *Br J Pharmacol*. 2004; 141:765–774. [PubMed: 14744801]
2. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. *Neuropharmacology*. 2004; 47:345–358. [PubMed: 15464149]
3. Mackie K. Cannabinoid receptors: where they are and what they do. *J Neuroendocrinol*. 2008; 20:10–14. [PubMed: 18426493]
4. Mackie K, Lai Y, Westenbroek R, Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. *J Neurosci*. 1995; 15:6552–6561. [PubMed: 7472417]
5. Mu J, Zhuang SY, Kirby MT, Hampson RE, Deadwyler SA. Cannabinoid receptors differentially modulate potassium a and d currents in hippocampal neurons in culture. *J Pharmacol Exp Ther*. 1999; 291:893–902. [PubMed: 10525114]
6. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. *Proc Natl Acad Sci U S A*. 1992; 89:3825–3829. [PubMed: 1315042]
7. Gebremedhin D, Lange AR, Campbell WB, Hillard CJ, Harder DR. Cannabinoid CB1 Receptor of cat cerebral arterial muscle functions to inhibit L-type Ca²⁺ channel current. *Am J Physiol: Heart Circ Physiol*. 1999; 276:H2085–H2093.
8. Pacher P, Bátkai S, Kunos G. The Endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol Rev*. 2006; 58:389–462. [PubMed: 16968947]
9. Turu G, Hunyady L. Signal transduction of the CB1 cannabinoid receptor. *J Mol Endocrinol*. 2010; 44:75–85. [PubMed: 19620237]
10. Mackie K. Cannabinoid receptors as therapeutic targets. *Annu Rev Pharmacol Toxicol*. 2006; 46:101–122. [PubMed: 16402900]
11. Grotenhermen F, Müller-Vahl K. The Therapeutic potential of cannabis and cannabinoids. *Dtsch Arztebl Int*. 2012; 109:495–501. [PubMed: 23008748]
12. Cridge BJ, Rosengren RJ. Critical appraisal of the potential use of cannabinoids in cancer management. *Cancer Manage Res*. 2013; 5:301–313.
13. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. *Nat Rev Drug Discovery*. 2002; 1:198–210. [PubMed: 12120504]
14. Bridges TM, Lindsley CW. G-Protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. *ACS Chem Biol*. 2008; 3:530–541. [PubMed: 18652471]

15. Burford NT, Clark MJ, Wehrman TS, Gerritz SW, Banks M, O'Connell J, Traynor JR, Alt A. Discovery of positive allosteric modulators and silent allosteric modulators of the μ -opioid receptor. *Proc Natl Acad Sci U S A*. 2013; 110:10830–10835. [PubMed: 23754417]
16. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, Walker G. Allosteric modulation of the cannabinoid cb1 receptor. *Mol Pharmacol*. 2005; 68:1484–1495. [PubMed: 16113085]
17. Horswill J, Bali U, Shaaban S, Keily J, Jeevaratnam P, Babbs A, Reynet C, Wong Kai P. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. *Br J Pharmacol*. 2007; 152:805–814. [PubMed: 17592509]
18. Navarro HA, Howard JL, Pollard GT, Carroll F. Positive allosteric modulation of the human cannabinoid (CB1) receptor by RTI-371, a selective inhibitor of the dopamine transporter. *Br J Pharmacol*. 2009; 156:1178–1184. [PubMed: 19226282]
19. Pamplona FA, Ferreira J, Menezes de Lima OM, Duarte FS, Bento AF, Forner S, Villarinho JG, Bellocchio L, Wotjak CT, Lerner R, Monory K, Lutz B, Canetti C, Matias I, Calixto JB, Marsicano G, Guimaraes MZP, Takahashi RN. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of cb1 cannabinoid receptor. *Proc Natl Acad Sci U S A*. 2012; 109:21134–21139. [PubMed: 23150578]
20. Ignatowska-Jankowska BM, Baillie GL, Kinsey S, Crowe M, Ghosh S, Owens RA, Damaj IM, Poklis J, Wiley JL, Zanda M, Zanato C, Greig IR, Lichtman AH, Ross RA. A cannabinoid cb1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects. *Neuropsychopharmacology*. 2015; 40:2948–2959. [PubMed: 26052038]
21. Bauer M, Chicca A, Tamborini M, Eisen D, Lerner R, Lutz B, Poetz O, Pluschke G, Gertsch J. Identification and quantification of a new family of peptide endocannabinoids (pepcans) showing negative allosteric modulation at cb1 receptors. *J Biol Chem*. 2012; 287:36944–36967. [PubMed: 22952224]
22. Kenakin TP. Biased signalling and allosteric machines: new vistas and challenges for drug discovery. *Br J Pharmacol*. 2012; 165:1659–1669. [PubMed: 22023017]
23. Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. *Pharmacol Rev*. 2010; 62:265–304. [PubMed: 20392808]
24. Jing L, Qiu Y, Zhang Y, Li JX. Effects of the cannabinoid CB1 receptor allosteric modulator Org27569 on reinstatement of cocaine-and methamphetamine-seeking behavior in rats. *Drug Alcohol Depend*. 2014; 143:251–256. [PubMed: 25169627]
25. German N, Decker AM, Gilmour BP, Gay EA, Wiley JL, Thomas BF, Zhang Y. Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure–activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl) pyridin-2-yl] phenyl} urea (PSNCBAM-1). *J Med Chem*. 2014; 57:7758–7769. [PubMed: 25162172]
26. Müller CE, Schiedel AC, Baqi Y. Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development. *Pharmacol Ther*. 2012; 135:292–315. [PubMed: 22728155]
27. Willard FS, Wooten D, Showalter AD, Savage EE, Ficorilli J, Farb TB, Bokvist K, Alsina-Fernandez J, Furness SG, Christopoulos A, Sexton PM, Sloop KW. Small molecule allosteric modulation of the glucagon-like peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin. *Mol Pharmacol*. 2012; 82:1066–1073. [PubMed: 22930710]
28. Sharma S, Rodriguez AL, Conn PJ, Lindsley CW. Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl) pyrimidine scaffold. *Bioorg Med Chem Lett*. 2008; 18:4098–4101. [PubMed: 18550372]
29. Urwyler S, Pozza MF, Lingenhoebl K, Mosbacher J, Lampert C, Froestl W, Koller M, Kaupmann K. *N,N'*-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4, 6-diamine (gs39783) and structurally related compounds: novel allosteric enhancers of γ -aminobutyric acid_B receptor function. *J Pharmacol Exp Ther*. 2003; 307:322–330. [PubMed: 12954816]
30. Urwyler S. Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives. *Pharmacol Rev*. 2011; 63:59–126. [PubMed: 21228259]

31. Brown, DJ. The Chemistry of Heterocyclic Compounds, the Pyrimidines. Vol. 52. John Wiley & Sons; New York: 2009. p. 4-6.
32. Fleming FF, Yao L, Ravikumar P, Funk L, Shook BC. Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. *J Med Chem*. 2010; 53:7902–7917. [PubMed: 20804202]
33. Levinson NM, Boxer SG. A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity. *Nat Chem Biol*. 2014; 10:127–132. [PubMed: 24292070]
34. Kubinyi, H. Hydrogen Bonding: The last mystery in drug design?. In: Testa, B. Waterbeemed, HVD. Folkers, G., Gay, R., editors. *Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical, and Computational Strategies*. Wiley-VCH; Zurich, Switzerland: 2001. p. 513-524.
35. Howlett, A. Cannabinoid receptor signaling. In: Pertwee, R., editor. *Cannabinoids*. Springer; Berlin, Heidelberg: 2005. p. 53-79.
36. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C, Trzaskos J, Caboche J, Girault JA. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. *J Neurosci*. 2003; 23:2371–2382. [PubMed: 12657697]
37. Ahn KH, Mahmoud MM, Kendall DA. Allosteric modulator Org27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and G_i protein- independent ERK1/2 kinase activation. *J Biol Chem*. 2012; 287:12070–12082. [PubMed: 22343625]
38. Khurana L, Ali HI, Olszewska T, Ahn KH, Damaraju A, Kendall DA, Lu D. Optimization of Chemical functionalities of indole-2-carboxamides to improve allosteric parameters for the cannabinoid receptor 1 (CB1). *J Med Chem*. 2014; 57:3040–3052. [PubMed: 24635495]
39. DeWire SM, Violin JD. Biased ligands for better cardiovascular drugs dissecting g-protein-coupled receptor pharmacology. *Circ Res*. 2011; 109:205–216. [PubMed: 21737816]
40. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, Shenoy SK, Lefkowitz RJ. A unique mechanism of β -blocker action: carvedilol stimulates β -arrestin signaling. *Proc Natl Acad Sci U S A*. 2007; 104:16657–16662. [PubMed: 17925438]
41. William AD, Lee ACH, Goh KC, Blanchard Sp, Poulsen A, Teo EL, Nagaraj H, Lee CP, Wang H, Williams M, Sun ET, Hu C, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW. Discovery of kinase spectrum selective macrocycle (16 e)-14-methyl-20-oxa-5, 7, 14, 26-tetraazatetracyclo [19.3. 1.1 (2, 6). 1 (8, 12)] heptacos-1 (25), 2 (26), 3, 5, 8 (27), 9, 11, 16, 21, 23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (cdks), janus kinase 2 (jak2), and fms-like tyrosine kinase-3 (flt3) for the treatment of cancer. *J Med Chem*. 2012; 55:169–196. [PubMed: 22148278]
42. Streeper RT, Pearson PG, Zhao Z, Mizsak SA, Vrbanc JJ. Synthesis of deuterium labeled 2,4-dipyrrolidinylpyrimidine as a chemical probe for P450 mediated oxidation of tirilazad mesylate. *J Labelled Compd Radiopharm*. 1998; 41:577–584.
43. Chi, DY., Lee, BS., Jung, Y., Sirion, U., Lim, YJ., Bae, YJ., Kim, H., Chu, SY., Moon, DH., Ryu, J-S., Kim, JS., Oh, SJ. 2-Arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as active ingredient. US. 8,497,260. 2013.
44. Sekiguchi, Y., Kanuma, K., Omodera, K., Tran, T-A., Semple, G., Kramer, BA. Pyrimidine derivatives and methods of treatment related to the use thereof. PCT/JP2005/006582. 2005.
45. Lebar MD, Hahn KN, Mutka T, Maignan P, McClintock JB, Amsler CD, van Olphen A, Kyle DE, Baker BJ. CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs. *Bioorg Med Chem*. 2011; 19:5756–5762. [PubMed: 21907583]
46. Yoshida K, Taguchi M. Reaction of N-substituted cyclic amines with 2, 4-dichloroquinazoline, 2, 4-dichloropyrimidine, and its 5-methyl derivative. *J Chem Soc, Perkin Trans 1*. 1992:919–922.
47. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid dna. *Mol Cell Biol*. 1987; 7:2745–2752. [PubMed: 3670292]
48. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem*. 1976; 72:248–254. [PubMed: 942051]

Figure 1.
Structures of representative allosteric modulators of the CB₁ receptor.

Figure 2.
 Designed and synthesized pyrimidinyl biphenyl ureas.

Figure 3.

CP55,940-induced GTP γ S levels in the presence and absence of varying concentrations of test allosteric modulators. HEK293 cell membranes expressing the CB₁ receptor were tested for GTP γ S levels in the absence and presence of compounds (A) **2**, (B) **7a**, (C) **7d**, (D) **8a**, (E) **8d**, and (F) **8r** at the indicated concentrations in the presence of CP55,940 (1 μM). The basal levels of $[^{35}\text{S}]\text{GTP}\gamma\text{S}$ binding was also measured in the absence of any orthosteric and allosteric ligand (basal CB₁), and its inhibition was tested by treatment with SR141716A (1 μM). Data are presented as a percentage of the GTP γ S levels in the presence of CP55,940 (1 μM). Each data point represents the mean $\pm$ SE (error bars) of at least three independent experiments performed in duplicate. Non-CB₁-mediated GTP γ S levels were measured by obtaining $[^{35}\text{S}]\text{GTP}\gamma\text{S}$ binding to membrane preparations transfected with vector PCDNA3.1 not incorporating the gene for CB₁ (no CB₁).

Figure 4.

Impact of compounds **7d** and **8d** on ERK1/2 phosphorylation. HEK293 cells expressing the CB₁ receptor were untreated (DMSO vehicle only) or treated with CP55,940 (0.5 μ M) or **2** (10 μ M), **7d** (10 μ M), and **8d** (10 μ M) for 5 min. Control siRNA or β -arrestin 1 siRNA or β -arrestin 2 siRNA or PTX (5 ng/mL) were used to treat the cells as indicated. Protein from cell lysates were separated on SDS-PAGE and analyzed by Western blots probed with phosph-ERK1/2 (p-ERK1/2). The total level of ERK1/2 detected is shown for comparison. Noted that the two bands correspond to the predominant isoforms, p42 (ERK2) and p44 (ERK1), for ERK1/2.

Scheme 1. Synthesis of Pyrimidinyl Biphenyl Ureas 7a–7h^a

^aReagents and conditions: (i) Na₂CO₃, Pd(PPh₃)₄, DME, H₂O, 90 °C, 7 h, 61%; (ii) SnCl₂·2H₂O, DCM/MeOH (1:1), 0 °C followed by reflux at 60°C, 4 h, 40%; (iii) DCM, 0 °C to rt, 2 h, 40–86%; (iv) pyrrolidine (for 7a–7d) or dimethyl amine (for 7e–7h), THF, reflux, 2–4 h, 35–81%.

Scheme 2. Synthesis of Pyrimidinyl Biphenyl Ureas 8a-8t^a

^aReagents and conditions: (i) amine **15** (**15a**, pyrrolidine; **15b**, NH(CH₃)₂; **15c**, MeNHEt; **15d**, NH(Et)₂; **15e**, piperidine; **15f**, cyclopropylamine; **15g**, azetidine), THF, rt, 2 h, 46%–80%; (ii) Na₂CO₃, Pd(PPh₃)₄, 1,4-dioxane, H₂O (4:1), 110 °C, 10 h, 46–75%; (iii) 10% Pd/C, H₂, EtOAc or ethanol, rt, 4 h, 38–97%; (iv) DCM, 0 °C–rt, 2 h, 25–86%; (v) BBr₃, DCM, 0 °C–rt; (vi) LiOH, THF/H₂O, rt.

Table 1

Allosteric Parameters of Analogues Derived from Scaffold 7 (7a–7h)

entry	compd	R ₁	R ₂	K _B (nM) ^a	α ^b
1	2	<i>p</i> -Cl	<i>N</i> -pyrrolidinyl	54.3 (21.9–134.6)	7.3
2	7a	<i>p</i> -Cl	<i>N</i> -pyrrolidinyl	226.9 (61.8–832.2)	11.6
3	7b	<i>p</i> -Br	<i>N</i> -pyrrolidinyl	394.9 (79.3–1964)	16.8
4	7c	<i>p</i> -F	<i>N</i> -pyrrolidinyl	195.6 (113.8–336.1)	3.5
5	7d	<i>p</i> -CN	<i>N</i> -pyrrolidinyl	167.8 (57.1–492.1)	10.5
6	7e	<i>p</i> -F	N(CH ₃) ₂	1116 (506.6–2459)	7.3
7	7f	<i>p</i> -CN	N(CH ₃) ₂	416.6 (308.1–563.2)	6.1
8	7g	<i>p</i> -I	N(CH ₃) ₂	965.3 (629.0–1481)	2.7
9	7h	<i>m</i> -F	N(CH ₃) ₂	967.4 (540.3–1722)	2.5

^a K_B: equilibrium dissociation constant of a potential allosteric ligand.

^b α: binding cooperativity factor for the tested allosteric modulator. The two allosteric parameters were tested using [³H]CP55,940 as the orthosteric ligand.

Table 2

Allosteric Parameters of Analogues Derived from Scaffold 8 with Variation of Substituents on the Phenyl Ring A (8a–8o)

entry	compd	R ₁	R ₂	K _B (nM) ^a	α ^b
1	2	<i>p</i> -Cl	<i>N</i> -pyrrolidinyl	54.3 (21.9–134.6)	7.3
10	8a	<i>p</i> -Cl	<i>N</i> -pyrrolidinyl	264.4 (61.9–1129)	18.1
11	8b	<i>p</i> -Br	<i>N</i> -pyrrolidinyl	101.9 (32.8–316.9)	6.1
12	8c	<i>p</i> -F	<i>N</i> -pyrrolidinyl	222.9 (154.2–322.1)	4.9
13	8d	<i>p</i> -CN	<i>N</i> -pyrrolidinyl	49.1 (27.9–86.3)	4.6
14	8e	<i>p</i> -F	N(CH ₃) ₂	1221 (849.6–1755)	5.2
15	8f	<i>p</i> -CN	N(CH ₃) ₂	313.3 (216.2–454.2)	4.5
16	8g	<i>p</i> -I	N(CH ₃) ₂	997.1 (480.7–2068)	2.5
17	8h	<i>m</i> -F	N(CH ₃) ₂	669.8 (173.6–2584)	2.0
18	8i	<i>p</i> -CF ₃	<i>N</i> -pyrrolidinyl	144.2 (85.8–242.4)	3.8
19	8j	<i>p</i> -CH ₃ C(O)	<i>N</i> -pyrrolidinyl	2108 (1299–3422)	2.5
20	8k	<i>p</i> -EtOC(O)	<i>N</i> -pyrrolidinyl	463.0 (51.8–4132)	1.6
21	8l	<i>p</i> -COOH	<i>N</i> -pyrrolidinyl	NB ^c	NB ^c
22	8m	<i>p</i> -OCH ₃	<i>N</i> -pyrrolidinyl	1826 (991.7–3364)	3.8
23	8n	<i>p</i> -OH	<i>N</i> -pyrrolidinyl	NB ^c	NB ^c
24	8o	<i>m</i> -CN	<i>N</i> -pyrrolidinyl	1980 (388.1–10100)	1.5

^a K_B: equilibrium dissociation constant of a potential allosteric ligand.

^b α: binding cooperativity factor for the tested allosteric modulator. The two allosteric parameters were tested using [³H]CP55,940 as the orthosteric ligand.

^c NB: no detectable binding or modulation of [³H]CP55,940 with the receptor using up to 32 μM of test compound.

Table 3

Allosteric Parameters of Analogues Derived from Scaffold 8 (8p–8t)

entry	Compd	R	K _B (nM) ^a	α ^b
13	8d		49.1 (27.9–86.3)	4.6
25	8p		211.0 (100.7–442.0)	4.5
26	8q		66.4 (24.9–176.4)	3.2
27	8r		69.6 (20.1–240.3)	4.8
28	8s		206.9 (110.3–388.1)	4.5
7	8f		313.3 (216.2–454.2)	4.4
29	8t		97.7 (13.4–711.0)	1.7

^aK_B: equilibrium dissociation constant of a potential allosteric ligand.^bα: binding cooperativity factor for the tested allosteric modulator. The two allosteric parameters were tested using [³H]CP55,940 as the orthosteric ligand.